Subject Index to Volume 72[1]

A

Acetylcholine
adrenocorticotropic hormone-induced grooming and, 838
nucleus tractus solitarii, in cardiovascular regulation, 801–802
Acetyl-coenzyme A, metabolic fate, in neonate, 522–523
Acid-base balance, amino acid oxidation and
hepatic, 433–435
intestinal, 421–422
mitrochondrial acid-base balance, 442–443
renal, 428
skeletal muscle, 427
whole body acid-base balance, 443
Activin, gonadal, 739
Acylcarnitine
cardiac electrical stability and, 921
cardiac ion transport and energy metabolism and, 921–922
Adenohypophysial hormones, erythropoiesis and, 462
Adenoma, thyroid, 684–685
Adenosine
in airways, 711
erythropoiesis and, 461
Adenosine 3',5'-cyclic monophosphate
cAMP-dependent protein phosphorylation modulation of brain sodium channels, S30–S31
cAMP-dependent protein phosphorylation modulation of other sodium channels, S31
hypothetical and existing examples of constitutive activation of cAMP cascade, 686–687
adenylate cyclase-coupled receptors, 686–687
cAMP-dependent protein kinase, 687
cyclase-activating guanosine triphosphate-binding protein, 687
negative controls of cAMP cascade, 687
in thyroid cell proliferation, 678–679
thyroid cell proliferation and differentiation induced by, 681–682
hypothetical and existing examples of constitutive activation of cAMP cascade, 686–687
Adenosinetriphosphatase, sodium-potassium, inhibition of, proximal renal tubular potassium conductance and, 8
Adenosine triphosphate. *See also* Energy balance
in airways, 711–712
erythrocyte, hemoglobin-oxygen affinity and, 302
intracellular
distal nephron potassium channels and, 17
potassium channels in Henle's loop and, 11
Adenylyl cyclase, in β-adrenergic receptor transduction system, 327
Adiadochokinesia, 1005–1006
Adipose tissue. *See* Brown adipose tissue; White adipose tissue
Adrenal hormones, angiogenesis and, 396–397
β-Adrenergic drugs, activation of erythrocyte membrane transport, 306–307
β-Adrenergic receptor
in asthma, 349–350
biochemistry, 324–326
in cystic fibrosis, 350
genetic regulation, 336
heterologous desensitization, 335–336
homologous desensitization, 334–335
hormonal regulation, 336–339
catecholamines, 336–338
glucocorticoids, 338–339
thyroid hormones, 338
in lung, 323–351. *See also* Lung
arachidonate metabolites and, 347–348
cytokines and, 348–349
inflammatory mediators and, 346–349
localization and function, 327–334
phospholipid-derived mediators and, 346–348
platelet-activating factor and, 347
reactive oxygen metabolites and, 348
in lung disease, 349–350
molecular aspects of receptor transduction system, 324–327
adenylyl cyclase, 327. *See also* β-Adrenergic receptor-adenylyl cyclase system
β-adrenergic receptor, 324–326
G proteins, 326–327
molecular aspects of regulation, 334–336
β-Adrenergic receptor-adenylyl cyclase system, respiratory
aging and, 341–342
in Basenji-Greyhound dog model of asthma, 345–346
diet and, 342–343
exercise and, 343
in experimental asthma, 344–345
in experimental atopy, 343–344
fetal development, 339–340
in infection, 346
in ontogenesis and aging, 339–342
postnatal maturation, 340–341
regulation in pathological conditions, 343–346
regulation in physiological conditions, 339–342
Adrenoceptors, in airways, 705–706
Adrenocorticotropic hormone (ACTH)
erythropoiesis and, 462
grooming behavior and, 833–836, 837–838. *See also* Grooming behavior
nucleus tractus solitarii, 797
serotonergic neuron growth and, 186
Afferent inputs, control of brain serotonergic neurons, 197–198
Afferent nerves, in airway control, 701–702
Afferent system, 72–74
Ia fibers
connection to motoneuron. *See* Monosynaptic reflex, afferent-motoneuron interface
spinal course and collateral system, 72–73
II fibers, spinal course and collateral system, 73
interaction with central programs in human posture and locomotion. *See* Human motor control
morphology of muscle spindle afferent fibers, 72–74
Aging
respiratory β-adrenergic receptor-adenylyl cyclase system and, 341–342
response to immersion and, 596
Aiming
cerebellar lesion and, 1005
cerebellum in, 1000–1003

[1] S prefix on page numbers indicates entries from Supplement to October issue.

Airways
adrenergic mechanisms in, 703
afferent nerves in, 701–702
C-fiber endings, 702
rapidly adapting (irritant) receptors, 702
slowly adapting (stretch) receptors, 701–702
cholinergic innervation, 702–703
cholinergic reflexes in, 703
inflammatory mediators in, 713–716
bradykinin, 715
cyclooxygenase products, 714–715
histamine, 713–714
lipoxygenase products, 715
other mediators, 715–716
serotonin, 714
modulation of neural transmission in. *See* Airways, neuromodulation
neural control
adrenergic mechanisms, 703
afferent nerves in, 701–702
cholinergic mechanisms, 702–703
nonadrenergic, noncholinergic neural mechanisms, 703–704
neuromodulation, 699–720
in asthma, 718–719
calcium channels in, 716–717
chloride channels in, 717–718
in chronic obstructive pulmonary disease, 719
definitions, 699–700
in disease, 718–719
inflammatory mediators in, 713–716
measurement of, 699–700
molecular probes, 700
neurotransmitter overflow, 699–700
postjunctional response, 700
mechanisms, 716–718
neurotransmitter receptors, 705–713
potassium channels in, 717
regulatory proteins, 718
scope of review, 699
sites of, 704–705
neurotransmitter receptors, 705–713
adenosine, 711
adenosine triphosphate, 711–712
adrenoceptors, 705–706
amino acid receptors, 712–713
muscarinic receptors, 706–708
neuropeptide receptors, 709–711
neuropeptide Y, 710–711
nicotinic receptors, 708
opioid receptors, 712
purinoceptors, 711–712
tachykinins, 709–710
vasoactive intestinal peptide, 709
nonadrenergic noncholinergic neural mechanisms, 703–704
parasympathetic ganglia in, 703
Aldosterone, suppression, natriuresis of immersion and, 576
in cirrhosis, 600
Aldosteronism, primary, immersion studies in, 611
Allogrooming. *See* Grooming behavior
Alveolar cells, β-adrenergic receptors, 332
Alveolar macrophages, β-adrenergic receptors, 332
Amino acid oxidation
cholesterogenesis, 439–440
comparting of urea cycle, 441–442
hepatic events, 428–436
acid-base balance, 433–435
assumptions, 430–431
energy balance, 433–435
metabolic pathways in liver, 440–441
observations, 435–436
oxidation of amino acids, 438–439
pathway of carbon and nitrogen flow, 431–433
intestinal events, 420–423
acid-base balance, 421–423
energy balance, 423
oxidation of amino acids, 439
metabolic processes, 436–438
mitrochondrial acid-base balance, 442–443
quantitative analysis, 419–446
cholesterogenesis, 439–440
comparting of urea cycle, 441–442
events in liver, 428–436
events in muscle, 423–428
events in small intestine, 420–423
intestinal oxidation of amino acids, 439
liver oxidation of amino acids, 438–439
metabolic pathways in liver, 440–441
metabolic processes, 436–438
mitochondrial acid-base balance, 442–443
problem to be analyzed, 420
role of urease, 441
whole body acid-base balance, 443
whole body energy balance, 436
renal events, 427–428
acid-base balance, 428
energy balance, 428
skeletal muscle events, 423–427
acid-base balance, 427
energy balance, 427
urease in, 441
whole body acid-base balance, 443
whole body energy balance, 436
Amino acids
in airways, 712–713
excitatory, nucleus tractus solitarii, in cardiovascular regulation, 802–803
inhibitory, nucleus tractus solitarii, in cardiovascular regulation, 803–804
neurotransmitters, nucleus tractus solitarii, in cardiovascular regulation, 802–804
substitutions, in gramicidin channels, S122–S123
γ-Aminobutyric acid
adrenocorticotropic hormone-induced grooming and, 837–838
nucleus tractus solitarii, in cardiovascular regulation, 803–804
2-Aminoethanesulfonic acid. *See* Taurine
***p*-Aminohippurate**, renal clearance, immersion and, 573
Anabolic steroids, angiogenesis and, 397
Analgesia, brain serotonergic neuron activity and, 206
Androgen-binding protein, 754–756
functions, 756
structure, 754–755
synthesis and secretion, 755–756
Anemia
in chronic disorders
erythropoietin deficiency and, 469
erythropoietin therapy, 470–471
in chronic renal failure
erythropoietin deficiency and, 468–469
erythropoietin replacement therapy, 469–470
of prematurity, erythropoietin therapy, 471
Angiogenesis
in cardiac muscle, 369–402
adaptation to external environmental changes, 377–378
adaptation to physical training and, 379–380

in adult, 377–384
during development, 376–377
development of collateral circulation in presence of limited blood supply, 391–392
hypertrophy and atrophy and, 384–385
larger vessel growth in presence of increased capillary supply, 389–390
long-term bradycardia and, 381
long-term vasodilatation and, 383–384
methodological considerations, 370–373
morphometric analysis, 371–372
stereological analysis, 370–371
myocardial infarction and, 387–389
vascular networks during phylogeny, 373
development of collateral circulation, 391–393
factors in, 392–399
growth factors, 394–395
hormones in, 395–397
adrenal hormones and angiotensin, 396–397
anabolic steroids, 397
insulin and diabetes, 395–396
thyroxine, 397
inhibition of, 399–400
larger vessel growth, 389–393
in muscles with increased capillary supply, 389–391
in muscles with limited blood supply, 391–393
mechanical factors, 397–399
acting from abluminal side of vessel, 399
acting from luminal side of vessel, 397–399
metabolic factors, 392–393
in pathological conditions, 384–389
in skeletal muscle, 369–402
adaptation to external environmental changes, 378–379
adaptation to physical training and, 380–381
in adult, 377–384
during development, 377
development of collateral circulation in presence of limited blood supply, 392–393
hypertrophy and atrophy and, 385–386
larger vessel growth in presence of increased capillary supply, 390–391
long-term electrical stimulation and, 381–383
long-term vasodilatation and, 383–384
methodological considerations, 370–373
morphometric analysis, 371–373
stereological analysis, 370–371
muscle regeneration and grafts, 386–387
vascular networks during phylogeny, 373–376
Angiogenic factor, 394
Angiopathy, diabetic, 395–396
Angiotensin. *See also* Renin-angiotensin-aldosterone system
angiogenesis and, 397
pressure natriuresis-diuresis and, 253
Angiotensin II
erythropoiesis and, 461
gonadal, 760
nucleus tractus solitarii, 798
in cardiovascular regulation, 807–808
Antigen(s), delivery into organized mucosal lymphoid tissue. *See* Mucosal immunity, antigen delivery
Antigen-presenting cells
enterocytes, 857
in organized mucosal lymphoid tissue, 856
Antihypertensive drugs
centrally acting, interaction with endogenous opioid peptides, nucleus tractus solitarii as possible site of, 811–812
renal function and, immersion studies, 608–609
Antioxidation
hypotaurine and, 130–133
taurine and, 135–136
Arachidonate metabolites. *See also specific metabolites*
in airways, 714–715
cardiac production and function, 903–906
in ischemia and reperfusion, 916–918
cyclooxygenase products, in airways, 714–715
lipoxygenase products, in airways, 715
pressure natriuresis-diuresis and, 253–255
respiratory β-adrenergic receptor function and, 347–348
Area postrema, serotonergic neurons in, 170
Arginine vasopressin
arterial blood pressure control and, 235
gonadal, 759–760
immersion and
influence of arginine vasopression suppression on immersion-induced diuresis, 586
plasma levels, 584–585
possible mechanisms of suppression, 586–588
urinary excretion, 583–584
nucleus tractus solitarii, 797
in cardiovascular regulation, 805–806
pressure natriuresis-diuresis and, 256
secretion, atrial stretch receptors and, 241–242
Arterial blood pressure
blood volume changes and, 263–278
acute autoregulatory responses, 263
acute hydraulic and reflex responses, 263
acute systemic autoregulation, 263–266
immediate responses to, 263–272
long-term functional changes of vascular sensitivity to prolonged volume expansion, 273–274
long-term structural adjustments of systemic vasculature to blood volume changes, 274–278
hypertrophy, 275–276
structural rarefaction, 276–278
myogenic response, 269
cellular basis, 269–271
physiological relevance, 271–272
neural-hormonal autoregulatory interactions in intact state, 272–273
ouabain theory, 266–267
predicted whole body response based on isolated organ responses, 267
proposed mechanisms of autoregulation, 267–269
vascular endothelium in, 269–271
electrical coupling, 270
endothelial contracting factors, 270
endothelin, 270–271
endothelium-derived relaxing factor, 270
signals for release of endothelial factors, 271
vascular wall renin, 270
body fluid volume and, 260–261
chronic renal function curves, 259–260
long-term control, 231–280
determinants of extracellular volume, 237–249. *See also* Extracellular volume
extracellular osmoregulation, 237
general theories, 232–237
neural regulation theory, 232–236
pressure-diuresis concept, 236–237
pressure natriuresis-diuresis in. *See* Pressure natriuresis-diuresis
neural regulation, 232–236
central neural control, 235–236

mechanoreceptor reflex control of vasopressin and renin secretion and their interactions, 235
relationships between acute and chronic renal function curves, 261–263
Arthropods, grooming behavior, 826
Asthma
β-adrenergic receptor function in, 349–350
airway neuromodulation in, 718–719
Basenji-Greyhound dog model, 225-adrenergic receptor-adenylyl cyclase system in, 345–346
experimental, 225-adrenergic receptor-adenylyl cyclase system in, 344–345
Atopy, experimental, 225-adrenergic receptor-adenylyl cyclase system in, 343–344
Atrial natriuretic factor
arginine vasopressin suppression during immersion and, 588
gonadal, 760–761
immersion and, 590–594
amino-terminal and carboxy-terminal portions of atrial natriuretic factor prohormone, 593
arginine vasopressin suppression during, 588
in cirrhosis, 601
natriuresis, 577–578
plasma levels, 591–592
urinary cyclic nucleotide excretion and, 593
nucleus tractus solitarii, 798
in cardiovascular regulation, 808
pressure natriuresis-diuresis and, 255–256
stretch-induced release, 243–245
water immersion and, atrial natriuretic factor infusion vs. immersion-induced augmentation of atrial natriuretic factor, 592–593
Atrial natriuretic peptide. *See* Atrial natriuretic factor
Atrial stretch receptors
extracellular volume and, 238–243
renal sympathetic nerve responses to, 240–241
renin-angiotensin-aldosterone responses to, 242–243
vasopressin responses to, 241–242
Atrophy
cardiac, angiogenesis and, 385
skeletal muscle, angiogenesis and, 385–386
Autocrine loop, in thyroid cell proliferation, 681
Autoregulation, arterial pressure and blood volume changes, 264–273
acute autoregulatory responses, 264
myogenic responses in, 269
cellular basis, 269–271
physiological relevance, 271–272
neural-hormonal autoregulatory interactions in intact state, 272–273
ouabain theory, 266–267
predicted whole body response based on isolated organ responses, 267
proposed mechanisms of rapid autoregulation, 267–269
quantification of acute systemic autoregulation, 264–266
vascular endothelium in, 269–271
Avian embryo, blood oxygen transport. *See* Blood oxygen transport, in early avian embryo
Axon, initial segments, sodium channels in, S34–S35

B

Bacteria, taurine in, 104–105
Baroreceptors
arginine vasopressin suppression during immersion and, 586–587
cardiac and arterial. *See also* Atrial stretch receptors
arterial blood pressure regulation, 232–235
nucleus tractus solitarii, 798–799
Basenji-Greyhound dog model, asthma, 225-adrenergic receptor-adenylyl cyclase system in, 345–346
Behavior, brain serotonergic neuron activity and, 206–207
Bicarbonate, erythrocyte, hemoglobin-oxygen affinity and, 310
Birds
grooming behavior, 826–827
taurine in, 105
Blood
oxygen transport, in avian embryo. *See* Blood oxygen transport, in early avian embryo
pH, in avian embryo, 945–946
blood carbon dioxide partial pressure and, 946
Blood flow, regional, redistribution, in immersion, 572
Blood glucose, brain serotonergic neuron activity and, 205
Blood oxygen transport, in early avian embryo, 941–962
adaptive changes during exposure to short-term and chronic hypoxia, 960–962
assessment of diffusion conditions for oxygen transport, 949–951
basic structure of extra- and intraembryonic circulatory system, 943
blood carbon dioxide partial pressure and acid-base status, 946
blood pH, 945–946
boundary conditions for, 943–952
calculation of in situ blood oxygen saturation and content in various parts of embryonic circulation, 957–959
dependence of red blood cell pH on extracellular pH, 948–949
determination of extraembryonic blood flow, 959
determination of oxygen partial pressure in embryonic tissue, 946–947
determination of pH and carbon dioxide and oxygen partial pressure in vitelline and intraembryonic circulation, 943–946
determination of pH in embryonic tissue, 947–948
effects of central shunt on intraembryonic oxygen supply, 952
embryonic oxygen uptake rate, 959–960
estimation of intraembryonic oxygen transport rates, 959–960
hypoxia and, 960–962
influence of organic phosphates on aggregation of hemoglobin P and hemoglobin D, 955–956
in vitro studies of effects of pH, carbon dioxide, and adenosine triphosphate on isolated specific embryonic hemoglobins, 953–954
ontogeny of hemoglobin types and red blood cell populations in avian embryo, 942–943
oxygenation in vitelline microcirculation: determination of capillary transit times and kinetics of oxygenation, 951–952
oxygen-binding properties of embryonic blood between days 3–8 of development, 956–957
oxygen partial pressure in embryonic blood, 944–945
hypoxia and, 960–962
oxygen transport function of embryonic blood, 953–960
red blood cell organic phosphate pattern, 954–955
Blood pressure
arterial. *See* Arterial blood pressure
immersion and, 569
Blood transfusion, autologous, erythropoietin in, 471
Blood vessels
capillary growth. *See* Angiogenesis
endothelium. *See* Vascular endothelium
long-term structural adjustments to blood volume changes
hypertrophy, 275–276
structural rarefaction, 276–278
Blood volume
arterial pressure and, 263–278. *See also* Arterial blood pressure, blood volume changes and
in avian embryo, hypoxia and, 960–961

central, immersion and, 568–569, 570–572. *See also* Water immersion, central blood volume and
B lymphocytes, in organized mucosal lymphoid tissue, 855
commitment to immunoglobulin A expression, 862–863
Body fluid volume
arterial pressure and, 260–261
extracellular. *See* Extracellular volume
Bombesin, nucleus tractus solitarii, 798
Bradycardia, long-term, effect on angiogenesis in cardiac muscle, 381
Bradykinin, in airways, 715
Brain
electrical stimulation, grooming behavior and, 838–839
glucose and fatty acid metabolism, in suckling-weaning transition, 534–535
lesions, grooming behavior and, 838
sodium channels
cAMP-dependent protein phosphorylation modulation of, S30–S31
developmental regulation of expression, S38–S39
protein kinase C modulation of, S31–S32
Brain serotonin system, 165–216
activity and actions of serotonergic neurons, 213–214
adult plasticity, 188–194, 214–215
collateral sprouting, 189–190
regeneration, 188–189
transplantation, 190–194
afferents, 171–172
anatomy, 166–180
afferents, 171–172
nuclei, 166–171
pathways and terminals, 172–175
receptor distribution, 175–177
ultrastructure, 177–179
cellular neurophysiology
unit activity in anesthetized animals or brain slices, 194–198
unit activity in behaving animals, 198–209
collateral sprouting of serotonergic neurons, 189–190
colocalization of 5-hydroxytryptamine with neuropeptides, 170–171
development, 180–188, 214
growth regulatory factors, 185–187
nuclei, 180–182
pathways and terminals, 182–183
tissue culture studies, 183–185
growth regulatory factors, 185–187, 215
gangliosides, 186–187
ions and small molecules, 185
neurotransmitters, 185–186
proteins, 187–188
historical perspective, 166
nonneuronal interactions, 171
nuclei
development, 180–182
inferior brain stem group, 169–170
area postrema, 170
development, 181–182
nucleus raphe magnus, 170
nucleus raphe obscurus, 169–170
nucleus raphe pallidus, 170
ventral lateral medulla, 170
nonserotonergic neurons in raphe nuclei, 170
superior brain stem group, 166–169
B9, 167–168
caudal linear nucleus, 166
development, 180–181
dorsal raphe nucleus, 167
median raphe nucleus, 166–167
pathways and terminals, 172–175
ascending system, 173–174
descending system, 172–173
development, 182–183
hippocampus, 183
neocortex, 183
nuclear organization of efferents, 175
subcortical, 182–183
postsynaptic actions, 209–212
cotransmission, 211
excitation/modulation, 210–211
inhibition/modulation, 210
latency and duration of action, 211–212
receptor distribution, 175–177
5-hydroxytryptamine$_1$, 175–176
5-hydroxytryptamine$_2$, 176–177
5-hydroxytryptamine$_3$, 177
regeneration of serotonergic neurons, 188–189
tissue culture studies, 183–185
accelerated maturation, 184
target cell interaction, 184–185
transplantation of serotonergic neurons, 190–194
descriptive studies and hyperinnervation, 191–192
electrophysiological maturation, 193
functional recovery, 193–194
host trophic factor, 192–193
role of target tissue, 192
two serotonergic systems, 215
ultrastructure of serotonergic neurons, 177–179
unit activity in anesthetized animals or brain slices, 194–198
afferent control, 197–198
development, 195–196
environmental/physiological manipulations, 198
feedback regulation, 196–197
intrinsic activity, 194–195
unit activity in behaving animals, 198–209
basic characteristics, 199–203
behavior and, 206–207
cardiovascular challenges and, 204–205
circadian variation, 202
environmental stressors and, 205–206
glucoregulatory challenge and, 205
in vivo release, 207–209
neurochemical identification, 199
in nociception and analgesia, 206
physiological manipulations, 203–205
sensory stimulation and, 202–203
in sleep-wake arousal cycle, 199–202
thermoregulatory challenges and, 203–204
Brain stem
lower, nucleus tractus solitarii afferents in, 794
serotonergic neurons. *See* Brain serotonin system
Brown adipose tissue
glucose metabolism, in neonate, 526
lipid metabolism, in neonate, 526–528
metabolism, in neonate, 526–528

C

Calcitonin, nucleus tractus solitarii, in cardiovascular regulation, 808
Calcitonin gene-related peptide
nucleus tractus solitarii, 798
in cardiovascular regulation, 808
ovarian, 764
Calcium
binding, taurine and, 115
in cell volume regulation, 1037–1056. *See also* Cell volume

intracellular
distal nephron potassium channels and, 17
potassium conductance in Henle's loop and, 11
proximal renal tubular potassium channels and, 4-5
kinetics, taurine and, 115-119
serotonergic neuron growth and, 185
taurine effects, 114-119
Calcium channels, in airway neuromodulation, 716-717
Capillary bed
capillary growth. *See* Angiogenesis
in skeletal and cardiac muscle during phylogeny, 373-376
heart, 373
skeletal muscle, 373-376
Carbohydrates
exogenous supply, in perinatal period, 512-513
metabolism, cardiac, fatty acid metabolism and, 893-894
Carbon dioxide
erythrocyte, hemoglobin-oxygen affinity and, 310
partial pressure, in embryonic blood (avian), acid-base status and, 946
Carbonic anhydrase activity, erythrocyte, in avian embryo, hypoxia and, 961
Carbon-14 studies, glycogen repletion, 1021-1029
Cardiac muscle, capillary growth in. *See* Angiogenesis
Cardiac output, immersion and, 568-569
Cardiovascular system
brain serotonergic neuron activity and, 204-205
regulation, nucleus tractus solitarii in. *See* Nucleus tractus solitarii
Carnitine, hepatic, in neonate, 521
Carnitine palmitoyltransferase, in fatty acid oxidation, in neonate, 521-522
Catecholamines
β-adrenergic receptor regulation and, 336-338
erythropoiesis and, 462
immersion and, 594-595
in cirrhosis, 601-602
Caudal linear nucleus, serotonergic neurons in, 167
Cell(s)
injury, stress response as marker for, 1074, 1076
shrinking, consequences, 1039-1040
stressed, heat shock proteins in, 1073-1074
stress-induced changes in physiology, 1064-1065
swelling, consequences, 1038-1040
volume. *See* Cell volume
Cell adhesion molecules, in lymphocyte-high endothelial venule interactions, 864-866
Cell culture, tissue hypoxia and erythropoiesis, 459-461
Cellular biology, voltage-gated sodium channels, S15-S41. *See also* Sodium channels
Cell volume
calcium regulation, 1044-1056
calcium dependence of regulatory volume decrease, 1045
calcium entry or calcium release, 1045-1046
calcium threshold for regulatory volume decrease(?), 1051-1052
controversy in calcium-dependent control of regulatory volume decrease, 1046-1051
correlation between swelling- and ionophore-induced activation, 1051
Ehrlich ascites tumor cells, 1049-1051
lymphocytes, 1047-1049
nature of calcium entry pathway, 1046
renal proximal tubule model of regulatory volume decrease mechanisms, 1052-1056
calcium entry and calcium release, 1053
calcium entry pathways under isotonic and hypotonic conditions: calcium channels, 1053-1054
calcium window: temporal dependence of regulatory volume decrease, 1055-1056
proximal straight tubule regulatory volume decrease response, 1052-1053
normal, control of, 1038
potassium channels and
distal nephron, 17
Henle's loop, 11-12
proximal renal tubule, 5-6
regulation, 1037-1056
calcium in. *See* Cell volume, calcium regulation
consequences of swelling and shrinking, 1038-1040
mechanisms of, 1040-1042
normal cell volume, 1038
phenomenological overview, 1039-1040
protein kinases and phosphatases in, 1043-1044
signaling pathways in regulatory volume decrease, 1043-1046
signaling pathways in regulatory volume increase, 1042-1043
transport mechanisms in regulatory volume decrease, 1041-1042
transport mechanisms in regulatory volume increase, 1040-1041
regulatory volume decrease
calcium in. *See* Cell volume, calcium regulation
protein kinases and phosphatases in, 1043-1044
signaling pathways in, 1043-1046
transport mechanisms in, 1041-1042
regulatory volume increase
signaling pathways in, 1042-1043
transport mechanisms in, 1040-1041
Cerebellar disorders
in humans, 1003-1006
aiming, pointing, and tracking and, 1005
myoclonus, 1004
nystagmus and, 1003-1004
postural reflexes and, 1004
pursuit eye movements and, 1004
reaction time and execution of movements in, 1004-1005
saccades and, 1004
timing and sequencing of movements and, 1005-1006
tremor, 1005
vestibuloocular reflex and, 1003
supraspinal motor control in, 57-58
Cerebellum
in conditioning of forelimb withdrawal, 995
control of reflex parameters, 991-995
conditioning of forelimb withdrawal, 995
eyeblink conditioning in rabbits, 993-995
locomotion, 995
optokinetic reflex, 993
vestibuloocular reflex, 991-993
visual placing, 995
corticopontine projections, 973-984
anatomic routes out of cerebellum, 982-983
comparative differences in, 981
connections from subcortical visual structures to pontine nuclei, 975-976
cytoarchitecture of pontine nuclei and distribution of corticopontine terminals within the pons, 976-977
differences in brain organization for movement: primates vs. other species, 983
differential distribution of sensory input to cerebellum and basal ganglia, 983-984
distinction between flocculus and paraflocculus, 981

parasagittal organization of afferent and efferent systems of cerebellar cortex, 981–982
pontine projections from cortical visual areas, 973–974
posterior parietal cortex, 974–975
visual climbing fiber afferents, 979–980
visual climbing fiber responses, 980–981
visual pontocerebellar projections, 978–979
visual responses in pons, 977–978
eyeblink conditioning in rabbits and, 993–995
Golgi tendon organ actions, 655–656
in locomotion, 57, 995
microphysiology of cerebellar cortex, 988–989
in optokinetic reflex, 993
parasagittal organization of afferent and efferent systems of cerebellar cortex, 981–982
in vestibuloocular reflex, 991–993
in visual guidance of movement, 967–1007
cerebellar control of reflex parameters, 991–995
cerebellar maps, 990
cerebellar symptoms in humans, 1003–1006. *See also* Cerebellar disorders, in humans
coordinate transformations, 990–991
corticopontine projections, 973–984
early studies of cerebellar function, 970–971
localization of function, 989–990
localization of visual cortical areas, 971–973
microphysiology of cerebellar cortex, 988–989
physiological studies in animals, 989–991
cerebellar maps, 990
coordinate transformations, 990–991
localization of function, 989–990
visual corticopontine projections, 973
visuomotor psychophysics, 984–988
voluntary movements, 995–1003
in visual placing, 995
visuomotor psychophysics, 984–988
comparison, 987
control strategies, 985
intermittent control, 985
motor learning, 987–988
motor memory, internal models, 986–987
parameter adjustment, 987
prediction, 987
theories of cerebellar function, 987–988
timing, 987
visual signals, 985–986
in voluntary movements, 995–1003
pursuit eye movements, 996–997
reaction time, 998–999
saccades, 997–998
short-term prism adaptation, 999–1000
visually guided limb movements: reaching, tracking, aiming, and pointing, 1000–1002
Cerebral cortex, Golgi tendon organ actions, 656
Charybdotoxin, binding by cloned potassium channels, S79–S80
Chloride, erythrocyte, hemoglobin-oxygen affinity and, 310
Chloride channels, in airway neuromodulation, 717–718
Cholecystokinin, nucleus tractus solitarii, 798
Cholesterogenesis, 439–440
Cholinergic nerves, in airway control, 702–703
Chronic obstructive pulmonary disease, airway neuromodulation in, 719
Circadian variation, in brain serotonergic neuron activity, 202
Circular dichroism spectroscopy, gramicidin channels, S120
Circulatory system, avian embryo, 943
Cirrhosis, decompensated. *See* Liver disease, decompensated
Clusterin, testicular, 761–762
c-*mos* oncogene, gonadal, 764–765
Collagen, type IV. *See* Extracellular matrix proteins
Colloid osmotic pressure, extracellular volume and, 246–247
Corticotropin-releasing factor
gonadal, 761
nucleus tractus solitarii, 796
Cyclic nucleotides, urinary excretion, relationship to atrial natriuretic factor during immersion, 593
Cysteamine, radioprotective effect, 133–134
Cysteine, detoxification, 134–135
Cystic fibrosis, β-adrenergic receptor function in, 350
Cytokines, respiratory β-adrenergic receptor function and, 348–349

D

Dendritic neuron model, S159–S183
analysis of transients for morphologically defined neurons, S171–S178
estimating electrotonic length using estimates of time constants from peel of transient, S175–S176
estimating system time constant without simulating transients, S178
how does system time constant depend on soma shunting factor, S176–S178
reduced unbranched "equivalent" cable models, S173–S174
theoretical time constants for different models, S171–S173
time constants of fully branched and unbranched models, S174–S175
voltage-clamp responses independent of soma shunting factor, S178
constrained inverse problem with different models, S178–S179
estimating parameter values from morphology and input resistance, S169–S171
comment on dendritic spines, S170–S171
comment on nonuniqueness, S170
comment on whole cell patch recording, S170
estimating membrane resistivity, S169–S170
glossary, S162–S163
historical aspects, S160
implications for neural integrative function, S180–S182
electrical compactness and efficacy of dendritic synpases, S181
impact of network activity on neuron cable properties, S181–S182
synaptic potential shape indexes, S181
linear vs. nonlinear models, S161
neuron models with realistic morphology: steady-state analysis, S163–S169
branch encoding for steady-state analysis, S165
cable encoding of neuron morphology, S164–S165
computing input conductance of a neuron, S165–S166
effective value of electrotonic length for nonideal trees, S169
normalized input resistance as a function of soma shunting factor, S168–S169
relation of dendritic membrane resistivity to input resistance of neuron, S168
robust factor relating dendritic input conductance to dendritic surface area, S166–S168
uncertainties, S179–S180
cytoplasmic resistivity, S180
nature of somatic shunt conductance, S180
shrinkage, S179–S180
voltage-dependent membrane conductances, S160–S161
Dendrotoxin, binding by cloned potassium channels, S80–S81

Diabetes mellitus
angiopathy in, 395–396
immersion studies in, 610–611
Diet
compositional changes
in perinatal period, 508
in suckling-weaning transition, 508–509
respiratory β-adrenergic receptor-adenylyl cyclase system and, 342–343
Displacement grooming, 827
Diuresis, immersion-induced, arginine vasopressin suppression and, 586. *See also* Arginine vasopressin, immersion and
Dopamine
adrenocorticotropic hormone-induced grooming and, 837
natriuresis of immersion and, 579
nucleus tractus solitarii, in cardiovascular regulation, 800–801
Dorsal raphe nucleus, serotonergic neurons in, 168
Drosophila, potassium channel gene family in, S74–S75
Drosophila melanogaster, *Shaker* mutant, potassium channels, S70, S82–S83. *See also* Potassium channels, cloning and characterization of potassium channel superfamily
Dynorphins, nucleus tractus solitarii, 797

E

Ehrlich ascites tumor cells, calcium-dependent control of regulatory volume decrease in, 1049–1051
Eicosanoids. *See* Arachidonate metabolites
Electrical stimulation
brain, grooming behavior and, 838–839
long-term, effect on angiogenesis in skeletal muscle, 381–383
Electrophysiological testing
interpretation of results, structure-related motoneuron properties and, 80–81
transplanted serotonergic neurons, 193
β-Endorphin, nucleus tractus solitarii, 797
Endothelial contracting factors, vascular smooth muscle tone and, 270
Endothelin
pressure natriuresis-diuresis and, 256
vascular smooth muscle tone and, 270–271
Endothelium. *See* Vascular endothelium
Endothelium-derived relaxing factor, vascular smooth muscle tone and, 270
Energy balance, amino acid oxidation and
hepatic, 433–435
intestinal, 422
renal, 428
skeletal muscle, 427
whole body energy balance, 436
Energy metabolism, glucose and fatty acid metabolism, in suckling-weaning transition, 540–541
Energy source, taurine as, 138–139
Energy storage, by taurine, 136–138
Enkephalins, nucleus tractus solitarii, 797
Enterocytes, in antigen presentation, 857
Enzymes
in cardiac phospholipid hydrolysis, 899–900
in cardiac phospholipid synthesis, 900
in cardiac triacylglycerol hydrolysis, 895–896
of fatty acid oxidation and ketogenesis, in perinatal period, 520–521
gluconeogenic
expression of genes encoding, in suckling-weaning transition, 529
in perinatal period, 513–514
glycolytic, expression of genes encoding, in suckling-weaning transition, 529
ion channels as, S91–S92
in triacylglycerol synthesis, 894–895
Eosinophils, β-adrenergic receptors, 333
Epidermal growth factor
gonadal, 751–752
thyroid cell proliferation and differentiation and, 677
Epinephrine, nucleus tractus solitarii, in cardiovascular regulation, 800
Epithelium, airway
β-adrenergic receptors in, 329
ion and water transport, β-adrenergic receptors in, 330–331
Erythrocyte
bicarbonate content, effect on hemoglobin-oxygen affinity, 310
carbon dioxide content, effect on hemoglobin-oxygen affinity, 310
chloride content, effect on hemoglobin-oxygen affinity, 310
embryonic (avian), 942–943
carbonic anhydrase activity, hypoxia and, 961
organic phosphate pattern, 954–955
hypoxia and, 961
oxygen affinity, hypoxia and, 961
pH, extracellular pH and, 948–949
populations, 942–943
magnesium content, effect on hemoglobin-oxygen affinity, 310–311
membrane ion transport and hemoglobin-oxygen affinity, 301–314
organic phosphate content
in avian embryo, 954–955
effect on hemoglobin-oxygen affinity, 302
ion pumping and, 302
pH and volume
control in absence of significant secondarily active cation or proton transport, 303–304
membrane transport and, 302–310
passive, 303–304
secondarily active transport, 304–310
secondarily active transport and, 304–310
activation by β-adrenergic drugs, 306–307
activation by intracellular acidification, 306
activation by osmotic disturbances, 305–306
effects on intracellular pH in physiological conditions, 307–310
osmotic shrinking and regulatory volume increase, 305–306
osmotic swelling and regulatory volume decrease, 305
urea content, effect on hemoglobin-oxygen affinity, 310
volume. *See also* Erythrocyte, pH and volume
in avian embryo, hypoxia and, 960
Erythropoietin, 449–472
assay methods and standardization, 453–454
biochemical aspects, 451–454
cells responsive to, 464–465
clinical applications, 469–471
pharmacological use in other anemias, 470–471
replacement therapy in renal failure, 469–470
deficiency, 468–469
anemia of chronic disorders and, 469
anemia of renal failure and, 468–469
historical background, 450–451
mechanism of action, 464–467
molecular biology, 451–452
normal plasma values, 454
overproduction, 467–468
tissue hypoxia and, 467
tumors and, 468
plasma kinetics, 463–464
dynamic formation, 463
metabolism, 463–464
production

adenohypophysial hormones and, 462
adenosine and, 461
catecholamines and, 462
extrarenal, 455–456
hepatic, 455–456
hypothalamus and humoral messengers and, 461–462
local messengers and, 461
paracrine and endocrine modulators, 461–462
pathophysiology, 467–469
prostanoids and, 461
renal, 454–455
renin-angiotensin II and, 461
sex steroids and, 462
sites of, 454–456
thyroid hormones and, 462
tissue hypoxia and, 456–461. *See also* Tissue hypoxia
tissue macrophages, 456
receptors, 465–466
signal transduction, 466–467
structure, 452–453
Estrous cycle, relaxin in, 741–742, 743
Exercise, respiratory β-adrenergic receptor-adenylyl cyclase system and, 343
Extracellular matrix proteins, gonadal, 748–749
functions, 749
localization, 748
regulation, 748–749
structure, 748
Extracellular volume
colloid osmotic pressure and, 246–247
determinants of, 237–249
differences between water immersion and saline-induced volume expansion, 572–573
neural-mechanical stretch receptors and, 238–243
renal sympathetic nerve responses, 240–241
renin-angiotensin-aldosterone responses, 242–243
vasopressin responses, 241–242
physical factors, 246–249
pressure natriuresis-diuresis and, 247–249
redistribution of body fluid compartments in immersion, 570–572
stretch-induced release of atrial natriuretic factor and other putative factors, 243–247
Extremity(ies), automatic functional movements. *See* Human motor control
Eyeblink conditioning, in rabbits, cerebellum in, 993–995
Eye movements
cerebellar lesion and, 1004
pursuit, cerebellum in, 996–997
saccades, cerebellum in, 997–998

F

Fatty acids
cardiac function and, 918–921
electrophysiological effects, 918–919
mechanical function, 920–921
exogenous supply, in perinatal period, 517
homeostasis, cardiac, 881–924
metabolism
during development. *See* Perinatal period; Suckling-weaning transition
in heart, 890–918. *See also* Heart, fatty acid metabolism
ischemic and reperfused. *See* Heart, reperfused; Myocardial ischemia
myocardial infarct size and, 919–920
oxidation
cardiac, 891–893
development of, 542
transport, in heart, 886–890
uptake, cardiac, 882–890
Fatty acyl-coenzyme A, cardiac ion transport and energy metabolism and, 921–922
Feedback regulation, brain serotonergic neurons, 197–198
Feeding behavior
in perinatal period, 508
in suckling-weaning transition, 508–509
Fetus, respiratory β-adrenergic receptor-adenylyl cyclase system, 339–340
Fibroblast growth factor
angiogenesis and, 394–395
gonadal, 752–753
Fibronectin. *See* Extracellular matrix proteins
Fish, taurine in, 105
Flexion reflex, conditioning of, cerebellum in, 995
Follicle regulatory protein, 745–746
functions in females, 745–746
functions in males, 746
localization and regulation, 745
Follicles, ovarian, 733
atresia, 734
Follistatin, 739
Forebrain
neuronal projections from nucleus tractus solitarii, 795
nucleus tractus solitarii afferents in, 794

G

Galanin, nucleus tractus solitarii, 798
Gangliosides, serotonergic neuron growth and, 186–187
Gastric motility, nucleus tractus solitarii in, 799
Gene(s)
potassium channel, human, S84
sodium channel
mutations in human sodium channel genes, S40–S41
hyperkalemic periodic paralysis, S40
molecular mechanisms of periodic paralyses, S40–S41
paramyotonia congenita, S40
tissue-specific regulation of expression, S39
Genetics, β-adrenergic receptor regulation, 336
Geriatric population, postural reflex function in, 50
Glomerular filtration, pressure natriuresis-diuresis and, 249
Glomerular filtration rate, immersion and, 574
Glucocorticoids, β-adrenergic receptor regulation and, 338–339
Gluconeogenesis
amino acid oxidation and. *See* Amino acid oxidation
in perinatal period, 513–516. *See also* Perinatal period
in human neonates, 541–542
in suckling-weaning transition period, 528
Glucose
conversion into hepatic glycogen. *See* Glycogen repletion
metabolism, during development. *See* Perinatal period; Suckling-weaning transition
serotonergic neuron growth and, 185
Glycogen, hepatic synthesis. *See also* Glycogen repletion
in suckling-weaning transition, 528–529
Glycogenolysis, hepatic, in perinatal period, 511–512
Glycogen repletion
definition of direct and indirect pathways, 1020–1021
glucose paradox(?), 1032
pathways, 1019–1033
definition of direct and indirect pathways, 1020–1021
glucose paradox(?), 1032

quantitation of pathway contributions, 1021–1029
regulation of, 1029–1030
three-carbon intermediates in indirect pathway, 1030–1032
quantitation of pathway contributions, 1021–1029
basis for concluding indirect pathway predominates, 1021–1023
evaluation of evidence, 1023–1029
glycogen to glucose specific activities and enrichments, 1026–1028
incorporation of carbon-14 from carbon-14-labeled carbon dioxide into glycogen, 1028–1029
incorporation of tritium from tritiated water, 1028
randomization of specifically labeled glucose, 1023–1025
tritium-to-carbon-14 ratios, 1025–1026
regulation of pathways, 1029–1030
effect of dietary protein, 1029–1030
effect of fed vs. fasted state, 1029
role of glucose vs. insulin, 1030
source and site of three-carbon intermediates in indirect pathway, 1030–1032
Glycolysis, hepatic, in suckling-weaning transition, 528–529
Glycosylation, sodium channel localization, S36
Goitrogenesis, 682–686
congenital defects, 683–684
general concepts, 682–683
Graves' disease, 683
sporadic goiter, 686
thyroid adenoma, 684–685
Golgi tendon organs, 623–658
activation by single motor units, 636–639
dynamic sensitivity of tendon organs, as demonstrated by responses to unfused contractions, 638–639
heterogeneity of motor units activating a single tendon organ, 637
lack of relation between discharge frequency and contractile force in responses to maximal tetani, 637–638
problems resulting from impossibility of measuring actual force applied to tendon organ, 636–637
responses to twitches of slow- and fast-contracting motor units, 637
association of tendon organs with other receptors, 629
central actions, 647–657
cerebellum, 655–656
cerebral cortex, 656
methodological problems related to selectively activating Ib fibers, 647–648
perception, 656–657
spinal cord, 648–655
cerebellar actions, 655–656
cerebral cortex actions, 656
development of, 627–628
discharges during natural movements, 644–647
human tendon organs, 646
methodological problems, 644–645
records obtained in freely moving animals, 645–646
distribution, 628–629
encoding properties, 633–644
activation by single motor units, 636–639
ensemble discharges of tendon organ population from a muscle, 642–643
nonlinearity of tendon organs: summary of causes, 643–644
passive muscle stretch and, 634–635
responses to combinations of motor units, 639–640
specific stimulus: contraction of in-series muscle fibers, 635–636
unloading of tendon organs by contraction of in-parallel muscle fibers, 640–642
functional properties, 629–647
discharges during natural movements, 644–647
encoding properties, 633–644
transduction, 629–633
Ib afferent fiber trajectories within spinal cord, 627
location, 624–625
mechanical properties: stress and strain, 630
morphology, 624–628
nonlinearity of tendon organs: summary of causes, 643–644
numbers in various muscles, 628
in perception, 656–657
ratios of motor units to tendon organs, 628–629
ratios of tendon organs to spindles, 629
receptor potentials, 630–631
spinal cord actions, 648–655
convergence in Ib pathways to motoneurons, 650–651
effects on γ-motoneurons, 655
identified interneurons in Ib lumbar circuits, 651–652
presynaptic inhibition, 652–653
reflexes, 653–654
segmental effects, 648–649
studies in humans, 654–655
structure, 625–627
transduction, 629–633
impulse initiation, 631–633
mechanical properties of tendon organs: stress and strain, 630
receptor potentials, 630–631
Gonadal peptides, 735–765
activin, 739
androgen-binding proteins, 754–756
arginine vasopressin, 759–760
atrial natriuretic factor, 760–761
clusterin, testicular, 761–762
c-*mos* oncogene cytostatic factor, 764–765
corticotropin-releasing factor, 761
criteria for factor identification and verification, 735
epidermal growth factor, 751–752
extracellular matrix proteins, 748–749
fibroblast growth factor, 752–753
follicle regulatory protein, 745–746
follistatin, 740
gonadotropin-binding inhibitors, ovarian, 763
gonadotropin-releasing hormone-like factors, 757–758
gonadotropin surge-inhibiting factor, ovarian, 762–763
growth factors, 749–754
inhibin, 735–739
"inhibin-like" hormones, 740–741
insulin-like growth factors, 749–750
luteinization inhibitor and stimulator, ovarian, 762
mullerian-inhibiting substance, 740
nerve growth factor, 754
neurohypophysial hormones, 758–760
neuropeptides, 763–764
oocyte meiosis inhibitor, 743–745
oxytocin, 758–759
peptides originally identified in other glands, 756–761
plasminogen activator, 746–748
platelet-derived growth factor, 754
P-Mod-S, testicular, 761
proenkephalin and prodynorphin peptides, 757
proopiomelanocortin peptides, 756–757
relaxin, 741–743
renin-angiotensin II, 760
seminal plasma inhibins, 740–741
transforming growth factor-α, 752
transforming growth factor-β, 753–754
Gonadotropin-binding inhibitors, ovarian, 763

Gonadotropin-releasing hormonelike factors, gonadal, 757–758
Gonadotropins
ovarian effects, 733–734
testicular effects, 732
Gonadotropin surge-inhibitng factor, ovarian, 762–763
G proteins
in β-adrenergic receptor transduction system, 326–327
modulation of sodium channels, S32
Gramicidin channels, S117–S123
amino acid substitutions, S122–S123
channel-forming activities of gramicidins modified at NH_2- or COOH-termini, S118–S119
channel function and membrane environment, S121–S122
channel insertion, S121
circular dichroism spectroscopy and hybrid channel formation, S120
conductance-concentration relations and conductance relaxations, S118
equilibrium gramicidin structure in membranes, S121
evidence for Urry model, S118–S120
fluorescence energy transfer, S119
gramicidin structure in solvents, S121
hybrid channel formation, S118
ion binding sites, S120
nonelectrolyte permeability, S118
nuclear magnetic resonance studies of carbon-13-enriched gramicidins, S119
nuclear magnetic resonance studies of gramicidins labeled at their termini, S119
sequence-substituted gramicidins, S120
side-chain orientations, S120–S121
solid-state nuclear magnetic resonance, S119–S120
from solvent to membrane, S121–S122
structure, S117–S118
two-dimensional hydrogen-1 nuclear magnetic resonance, S119
vibrational spectroscopy, S119
voltage-dependent, S122
Graves' disease, goitrogenesis in, 683
Gravity, influence on postural reflexes, 42–43
Grooming behavior
aberrant, opioids and, 836–837
adrenocorticotropic hormone-induced, 833–836, 837–838
acetylcholine in, 838
γ-aminobutyric acid in, 837–838
dopamine in, 837
grooming bout, 833
5-hydroxytryptamine in, 838
neurotransmitter systems and, 837–838
opioid systems in excessive grooming, 836
specificity of, 834–835
structure-activity studies with adrenocorticotropic hormone, 835–836
allogrooming (social grooming), 828–832
body hygiene and, 829
reconciliation and, 831–832
regulation of social tension and, 831
social functions of, 829–830
social relationships and, 830–831
in arthropods, 826
in birds, 826–827
brain lesions and, 838
dearousal and, 828
displacement grooming, 827
electrical brain stimulation and, 838–839
ethology and neurobiology, 825–841
excessive, peptide-induced, opioid systems in, 836
functional aspects of grooming, 826–832
allogrooming (social grooming), 828–832
in arthropods, 826
in mammals, 827–832
preening and associated behaviors in birds, 826–827
in mammals, 827–832
neural substrate, 832–839
adrenocorticotropic hormone/melanocyte-stimulating hormone-controlled grooming, 833–836
brain structures involved in grooming, 838–839
neurotransmitter systems and adrenocorticotropic hormone-induced grooming, 837–838
opioid systems in peptide-induced excessive grooming, 836–837
peripheral vs. central control, 832–833
peripheral vs. central motor control, 832–833
Growth factors
angiogenesis and, 394–395
gonadal, 749–754
serotonergic neuron growth and, 185–187
Growth hormone, erythropoiesis and, 462

H

Heart
arachidonate metabolite production and function, 903–906
ischemia and reperfusion and, 916–918
physiological role of eicosanoids in normal heart, 905–906
regulation of eicosanoid production, 905
site of eicosanoid production, 904
synthetic pathways, 904
atrophy, angiogenesis and, 385
capillary growth. *See* Angiogenesis
capillary supply during phylogeny, 373
collateral circulation, development of, 391–392
fatty acid homeostasis, 881–924
fatty acid metabolism, 890–906
arachidonic acid metabolites, 903–906
carbohydrate metabolism and, 893–894
fatty acid activation, 891
fatty acid oxidation, 891–893
fatty acids in cardiac lipid pools, 894–902
in ischemic and reperfused heart, 906–918. *See also* Heart, reperfused; Myocardial ischemia
platelet-activating factor, 906
spatial and cellular differences in, 902–903
tissue levels of fatty acyl moieties, 890–891
fatty acid oxidation, 891–893
cardiac capacity for, 892–893
control of, 892
effects of maturation on, 903
esterification versus, 892
fatty acid activation, 891
mitochondrial, 891
peroxisomal, 891
fatty acid transport, 886–890
endothelial delivery of fatty acids, 886–888
interstitial, 888
intracellular, role of cytoplasmic fatty acid-binding proteins, 889–890
transendothelial, 888
transsarcolemmal, 888–889
fatty acid uptake, 882–890
extracellular fatty acid sources, 882
fatty acid release from circulating triacylglycerols, 883–886
myocardial fatty acid transport, 886–890

functional effects of lipid amphiphiles, 918–924
biological effects of lysophospholipids, 922–924
fatty acids, 918–921
fatty acyl-coenzyme A and acylcarnitine, 921–922
uncertainties regarding detrimental effects, 924
hypertrophy, angiogenesis and, 384–385
lipoprotein lipase in, 883–886
binding at endothelium, 884
cellular transport of, 885
hydrolytic action, 883
ischemia and, 911
localization and release of, 884
origin of, 883–884
regulation of activity, 884–885
long-term, 885–886
phospholipids, 894
biosynthesis, 900
in cardiac membranes, 898–899
enzymatic hydrolysis, 899–900
fatty acids in, 897–898
regulation of biosynthesis and hydrolysis, 900–902
turnover, 899
platelet-activating factor production and function, 906
potassium channels in, S83–S84
reperfused
eicosanoid production in, 916–918
fatty acid metabolism, 906–918
restoration of, 908
tissue levels of fatty acids, 908–909
lysophospholipids in, 923–924
phospholipid metabolism
degradation, 913
mechanisms underlying hydrolysis, 914–915
phospholipid resynthesis on reperfusion, 915–916
platelet-activating factor in, 918
triacylglycerol turnover in, 911
transplantation. *See* Transplantation
triacylglycerol-fatty acid cycle, 897
triacylglycerols, 894
biosynthesis
enzymes in, 894–895
regulation of, 896
enzymatic hydrolysis, 895–896
regulation of, 896–897
vascular growth during development, 376–377
Heat shock proteins, 1063. *See also* Stress response
HSP 28, 1067–1068
HSP 60 (groEL) family, 1068–1069
HSP 70 family, 1070–1071
HSP 90 family, 1069–1070
HSP 110, 1070
role in cells experiencing stress and their possible mode of regulation, 1073–1074
role in facilitating protein folding and assembly, 1071–1073
structure and function, 1065–1071
ubiquitin, 1066–1067
Heat shock response. *See* Stress response
"Height vertigo", 47
Hemoglobin, embryonic (avian), 942
influence of organic phosphates on aggregation of HbP and HbD, 955–956
oxygen transport, in vitro studies of effects of pH, carbon dioxide, and adenosine triphosphate, 953–954
timing of swith to adult hemoglobin production, oxygen pressure and, 961
Hemoglobin-oxygen affinity
adrenergic control in teleost fish, 311–314
activation of sodium-proton exchange by catecholamines in vivo, 311–313
adrenergic control of blood oxygen transport in some teleost fish, 313–314
effects of adrenergic stimulation on blood oxygen transport in vivo, 313
effects of adrenergic stimulation on erythrocyte pH and nucleoside triphosphate concentrations in vivo, 313
factors affecting blood catecholamine concentrations, 311
in avian embryos, 953. *See also* Blood oxygen transport, in early avian embryo
hypoxia and, 961
bicarbonate and, 310
chloride and, 310
control in hypoxic lampreys, 314
erythrocyte membrane ion transport and, 301–314
adrenergic control in teleost fish, 311–314
bicarbonate, 310
carbon dioxide, 310
chloride, 310
control in hypoxic lampreys, 314
magnesium, 310–311
organic phosphates, 302
urea, 310
erythrocyte pH and volume and, 302–310. *See also* Erythrocyte, pH and volume
erythropoiesis and, 457–458
hemoglobin concentration and, 302–303
magnesium and, 310–311
protons and, 302
urea and, 310
Heterologous desensitization, β-adrenergic receptor, 335–336
Hippocampus, 5-hydroxytryptamine immunoreactive fibers in, 183
Histamine
in airways, 713–714
nucleus tractus solitarii, in cardiovascular regulation, 801
Histogram, unit excitatory postsynaptic potential, 90–91
Hodgkin-Huxley paradigm, S50–S51. *See also* Potassium channels
Homologous desensitization, β-adrenergic receptor, 334–335
Hormones
angiogenesis and, 395–397
changes in
in perinatal period, 509–510
in suckling-weaning transition, 510–511
distal nephron potassium channels and, 17–18
fatty acid oxidation and ketogenesis and, in neonate, 523–524
gonadal peptides, 735–765
induction of cytosolic phosphoenolpyruvate carboxykinase, in perinatal period, 514
inhibin family, 735–741
lipid metabolism in brown adipose tissue and, 527–528
potassium channels in Henle's loop and, 11–12
proximal renal tubular potassium conductance and, 6
response to immersion, physiological determinants, 595–596
thyroid growth and, 674
H-reflex, in human posture and locomotion, 39–40
Human motor control
body's center of mass and, 48
central programming, 34–38
interlimb coordination, 36–37
muscle activation before foot contact, 35
postural adjustments during voluntary arm and leg movements, 35–36

postural adjustments to perturbations, 36
in rigidity, 56
selection of appropriate programs, 37–38
in spastic paresis, 54
upper and lower limb muscles, 52
central program-reflex interaction, 48
in cerebellar disorders, 57–58
differences in behavior of leg extensor and flexor muscles, 43–44
generation of appropriate response pattern, 48
in geriatric population, 50
interaction between central program and afferent input, 33–58
maturation of locomotor pattern, 49–50
modification of central mechanism and reflex function, 48–53
adaptational changes, 51
age-related changes, 49–50
developmental changes, 49–50
in geriatric population, 50
motor control in upper and lower limb muscles, 52–53
short- and long-term adaptation, 50–52
training-induced neuronal changes, 51–52
motor control in upper and lower limb muscles, 52–53
central mechanisms, 52
proprioceptive reflexes, 52–53
polysynaptic (long latency) reflexes, 40–42
reflex behavior, 41–42
reflex origin, 40–41
proprioceptive reflex systems, 38–44
differences in behavior of leg extensor and flexor muscles, 43–44
influence of gravity on postural reflexes, 42–43
polysynaptic (long latency) reflexes, 40–42
posture and locomotion, 39
in rigidity, 56–57
running, 39–40
in spastic paresis, 54–55
upper and lower limb muscles, 52–53
utilization of group I afferent input, 38–39
in rigidity, 55–57
in spastic paresis, 53–55
supraspinal control mechanisms, 53–58
in cerebellar disorders, 57–58
in rigidity, 55–57
in spastic paresis, 53–55
systems involed in, 34–48
vestibular system in, 44–46
limitations in postural adjustments, 45–46
postural sway adjustment, 44–45
visual system in, 46–47. *See also* Cerebellum, in visual guidance of movement
visual compensation for defective afferent input, 46–47
visual destabilization, 47

Hydrogen ion, secretion, distal nephron potassium channels and, 19

Hydrophobicity index, in modeling ion channels, S97

Hydrostatic pressure gradient, role in central blood volume response to immersion, 570

5-Hydroxytryptamine
adrenocorticotropic hormone-induced grooming and, 838
central nervous system. *See* Brain serotonin system

Hygiene, grooming behavior and, 829

Hyperkalemic periodic paralysis, genetic mutations in human sodium channel genes, S40

Hypertension. *See also* Arterial blood pressure
essential, immersion studies, 605–608
effects of antihypertensive agents on renal function, 608–609
reduced renal excretory function and, 258–259
renal cross-transplantation studies, 259

Hypertrophy
cardiac, angiogenesis and, 384–385
skeletal muscle, angiogenesis and, 385–386
vascular wall, blood volume changes and, 275–276

Hypotaurine, antioxidant effect, 130–133

Hypothalamus, erythropoiesis and, 461–462

Hypoxia
adaptive changes of blood oxygen transport in avian embryo, 960–962
blood and red blood cell volume, 960–961
influence of hypoxia on red blood cell-phosphate pattern, carbonic anhydrase activity, and oxygen affinity, 961–962
influence of oxygen pressure on timing of switch from embryonic to adult hemoglobin, 961
angiogenesis in cardiac muscle and, 377–378
angiogenesis in skeletal muscle and, 378–379
tissue. *See* Tissue hypoxia

I

Immersion. *See* Water immersion

Immunization, mucosal
strategies for, 871–873
vaccine delivery into organized mucosal lymphoid tissue, 871–872
vaccine requirements, 871

Immunoglobulins
α-heavy chain isotype switch in organized mucosal lymphoid tissue, 862
T-cells and lymphokines in, 862–863
IgA, transepithelial transport, 867–868
binding of IgA to polymeric immunoglobulin receptor, 868
polymeric immunoglobulin receptor and its intracellular trafficking, 867–868
secretory IgA, mucosal immunity and
mechanisms of, 868–870
mucosal effector antibody, 866–867
regulation of mucosal immune response, 863

Immunology
molecular and cellular basis of immune protection of mucosal surfaces. *See* Mucosal immunity
stress response and, 1076–1077

Infant
anemia of prematurity, erythropoietin therapy, 471
newborn, glucose and fatty acid metabolism in humans, 541–543
development of fatty acid oxidation, 542
essential role of gluconeogenesis, 541–542
hormonal changes and, 541
interrelations between fatty acid oxidation, gluconeogenesis, and glucose utilization, 542–543
respiratory β-adrenergic receptor-adenylyl cyclase system, 340–341
suckling-weaning transition. *See* Suckling-weaning transition

Infection, respiratory, 225-adrenergic receptor-adenylyl cyclase system in, 346

Inflammatory mediators
β-adrenergic receptor function and, 346–349
in airways, 713–716

Inhibin, gonadal, 735–739
actions, 738–739
localization, 737
regulation, 737–738
seminal plasma inhibins, 739–740
structure, 735, 737

Insects, taurine in, 105

Insulin
diabetic angiopathy and, 395–396
glycogen repletion and, 1030

Insulin-like growth factor(s), gonadal, 749–750
function and activities, 750
localization, 749
receptors, 750
regulation, 749–750
Intestine
glucose and fatty acid metabolism, in suckling-weaning transition, 539–540
mucosal surfaces, immune protection of. *See* Mucosal immunity
Intestine, small, amino acid oxidation, 420–423, 439
acid-base balance, 421–422
energy balance, 422
urease in, 441
Inulin, renal clearance, immersion and, 573
Invertebrates, taurine in, 105
Iodide, thyroid cell proliferation and, 677
Iodine
metabolism, congenital defects, goitrogenesis and, 683–684
thyroid growth and, 674
Ion channels
activation
agonist-activated channels, S112
energetics of, S110–S114
gating charge, S111–S112
kinetics, S114–S115
multistate channels, S112–S114
two-state channel, S110–S112
voltage-dependent channels, S111
agonist-activated channels, S112, S123–S132. *See also* Nicotinic acetylcholine-gated channels
electrostatic interactions
Born energy, S98–S99
ion-channel electrostatics, S99–S100
as enzymes, S91–S92
control of channel function, S91
turnover numbers, S91
uniqueness, S91–S92
gating, S109–S117
activation kinetics, S114–S115
control of, S110
energetics of channel activation, S110–S114
molecular gating models, S116–S117
gramicidin channels, S117–S123
inactivated states, S112
ion-channel interactions, S98–S103
long-range electrostatic interactions, S98–S100
short-range solvation, S101–S103
surface potentials, S100–S101
ion selectivity, S108–S109
equilibrium binding, S108
exclusion, repulsion, S109
reversal potential movements, S108–S109
kinetics of ion movement, S104–S108
ion binding, S105–S106
ion entry, S106–S107
ion movement through pore (ion translocation), S107–S108
singly occupied channels, S104–S105
kinetic states, S112–S113
model building, S94–S98
hydrophobicity indexes, S97
model development, S97, S95
tests of models, S97–S98
molecular determinants of function, S89–S141
channels are enzymes, S91–S92
gating, S109–S117
ion-channel interactions, S98–S103
model building, S94–S98
permeation, S103–S109
specific channel classes, S117–S136
structure, S92–S94
structure function studies, S136–S141
in neurons, S160–S161
nicotinic acetylcholine-gated, S123–S132
permeation, S103–S109
fixed vs. fluctuating pore, S103–S104
ion selectivity, S108–S109
kinetics of ion movement, S104–S108
structure, S92–S94
primary sequences, S92
subunit composition, stoichiometry, and topology, S92–S93
tertiary and quarternary structure, S93–S94
structure-function studies, S136–S141
changes in surface residues, S138
crystal vs. solution or membrane structures, S137
importance of structural information, S136–S137
internal residues and stability of folded proteins, S138–S139
limited energetic window, S141
modifying membrane channels, S139–S140
sensitivity of active sites to small structural changes, S139
spectroscopic approaches, S140–S141
structural equivalence of mutants, S137–S139
structural information about mutant membrane channels, S139–S141
structural information from functional measurements, S141
voltage-gated, S5–S12, S132–S136. *See also* Potassium channels; Sodium channels
cross-membrane ion effects, S6–S7
gating, S134–S135
gating charge as signal of conformational change, S134–S135
gating currents, S9–S10
gramicidin channels, S123
Hodgkin-Huxley paradigm, S50–S51
inactivation and channel block as evidence of conformational change, S135
inactivation gate, mechanism of inactivation, S10–S11
ion permeation, S136
ion transport across membranes, S5–S6
localization of gates, S11–S12
measures of transport rate, S6
model gating behavior, S135
necessity of gates, S7–S8
number of gates on each pore, S7
origin of voltage sensitivity, S8
pore location in channel peptide, S7
pore size, S6
sigmoid opening, exponential closing, S8–S9
subunit composition and structure, S132–S134
tetrodotoxin/saxitoxin block, S135–S136
Ion transport. *See also* Ion channels, permeation
airway epithelium, β-adrenergic receptors in, 330–331
cell volume regulation, 1040–1042
in erythrocyte membranes, hemoglobin-oxygen affinity and. *See* Hemoglobin-oxygen affinity
how ions cross membranes, S5–S6
measures of transport rate, S6
Ischemia
cardiac. *See* Myocardial ischemia
collateral circulation in, 391–393
Isethionic acid, taurine and, 141–142

K

Kallikrein-kinin system
natriuresis of immersion and, 579–580
pressure natriuresis-diuresis and, 255
Kidney
amino acid oxidation, 427–428
arterial blood pressure regulation, 236–237
blood flow, lowered, erythropoiesis and, 458
chronic renal function curves, 259–260
relation to acute renal function curves, 261–263
effects of head-out water immersion. *See* Water immersion, renal effects in humans
epithelial transport regulation. *See* Renal epithelial transport
erythropoietin production, 454–455
excretory function, reduced, hypertension and, 258–259
function, effects of antihypertensive agents, immersion studies, 608–609
glucose and fatty acid metabolism, in suckling-weaning transition, 533–534
kallikrein-kinin system
natriuresis of immersion and, 579–580
pressure natriuresis-diuresis and, 255
pressure natriuresis-diuresis, 247–249. *See also* Pressure natriuresis-diuresis
proximal tubule, model of calcium-dependent regulatory volume decrease mechanisms, 1052–1056. *See also* Cell volume, calcium regulation
sodium handling, immersion and, 574–581. *See also* Water immersion, renal effects in humans
sympathetic nerve activity, atrial stretch receptors and, 240–241
transplantation. *See* Transplantation
water handling, in cirrhosis, immersion and, 597
Kidney failure, chronic, anemia in, erythropoietin deficiency and, 468–469

L

Laminin. *See* Extracellular matrix proteins
Lamprey
erythrocyte pH, effects of secondarily active ion transport mechanisms, 307–308
hypoxic, control of hemoglobin-oxygen affinity in, 314
Leukotrienes, in airways, 715
Lipid(s)
mobilization, during suckling-weaning transition, 538–539
storage, during suckling-weaning transition, 537–538
Lipid amphiphiles, cardiac function and, 918–924
Lipid metabolism, hepatic, in suckling-weaning transition, 531–533
Lipoprotein lipase, cardiac activity. *See* Heart, lipoprotein lipase in
Liver
amino acid oxidation, 428–436, 438–439
acid-base and energy balances, 433–435
assumptions, 430–431
comparting of urea cycle, 441–442
metabolic pathways, 440–441
mitochondrial acid-base balance, 442–443
observations, 435–436
pathway of carbon and nitrogen flow, 431–433
cholesterogenesis, 439–440
erythropoietin production, 455–456
fatty acid oxidation and ketogenesis
carnitine palmitoyltransferase activity regulation, 521–522
hormonal control, 523–524
increase in enzyme activity, 520–521
metabolic fate of mitochondrial acetyl-coenzyme A, 522–523
partition of long-chain fatty acyl-coenzyme A between triacylglycerol and acylcarnitine formation, 520
pathways for, 518–520
in perinatal period, 518–524
regulation of fatty acid uptake and acyl-coenzyme A formation, 520
glucose and fatty acid metabolism, in suckling-weaning transition, 528–533
glycogenolysis, in perinatal period, 511–512
glycogen repletion, 1019–1033. *See also* Glycogen repletion
mitochondrial oxidative capacity, maturation of, initiation of gluconeogenesis and, 515
oxygenation, initiation of gluconeogenesis and, 514–515
taurine in, 106
triacylglycerol stores, mobilization in perinatal period, 517
Liver disease, decompensated
immersion studies, 596–603. *See also* Water immersion
natriuresis of immersion in, 598–603
aldosterone and, 600
atrial natriuretic factor and, 601
characterization, 598–599
mechanism of, 599–602
plasma catecholamines and, 601–602
potential therapeutic application, 602–603
renal prostaglandins and, 600–601
Locomotion
cerebellum in, 57, 995
human. *See* Human motor control
Lung
β-adrenergic receptor-adenylyl cyclase system
aging and, 341–342
diet and, 342–343
exercise and, 343
fetal development, 339–340
postnatal maturation, 340–341
regulation in physiological conditions, 339–342
β-adrenergic receptor localization and function, 327–334
airway epithelium, 329
airway smooth muscle, 328–329
alveolar cells, 332
alveolar macrophages, 332
cholinergic transmission, 328
ciliated cells and mucociliary clearance, 329–330
eosinophils, 333
ion and water transport in airway epithelium, 330–331
mast cells, 332–333
mononuclear phagocytes and lymphocytes, 334
neutrophils, 333–334
nonresident immune cells, 333–334
resident immune cells, 332–333
submucosal glandular secretion, 331–332
sympathetic innervation and regulation of airway tone, 328
β-adrenergic receptor regulation
catecholamines, 336–338
glucocorticoids, 338–339
hormonal, 336–339
molecular aspects, 334–336
thyroid hormones, 338
Lung disease
β-adrenergic receptor function in, 349–350
chronic obstructive, airway neuromodulation in, 719
Luteinization inhibitor and stimulator, ovarian, 762

Lymphocytes. *See also* B lymphocytes; T lymphocytes
β-adrenergic receptors, 334
calcium-dependent control of regulatory volume decrease in, 1047–1049
homing specificities in mucosal tissues, 863–866
cell adhesion molecules in lymphocyte-high endothelial venule interactions, 864–866
distribution, 864
modulation of, 866
intraepithelial, in diffuse mucosal lymphoid tissue, 856
lamina propria, in diffuse mucosal lymphoid tissue, 857
potassium channels in, S83
Lymphoid cells, in organized mucosal lymphoid tissue, 855–856
Lymphoid tissue, mucosal. *See* Mucosal immunity
Lysophospholipids
during cardiac reperfusion, 923–924
in myocardial ischemia, 922–923

M

Macrophages
alveolar, β-adrenergic receptors, 332
tissue, erythropoietin production, 456
Magnesium
erythrocyte, hemoglobin-oxygen affinity and, 310–311
intracellular, potassium channels in Henle's loop and, 11
Malonyl-coenzyme A, hepatic, in neonate, 521–522
Mammals
grooming behavior, 827–832
stress response, 1063–1077. *See also* Stress response
taurine in, 105
Mast cells, pulmonary, β-adrenergic receptors, 332–333
Maximum likelihood estimator, unit excitatory postsynaptic potential, 91
M-cells. *See* Mucosal immunity, antigen delivery
Median raphe nucleus, serotonergic neurons in, 167–168
Medulla
ventral lateral, serotonergic neurons in, 170
ventrolateral, neuronal projections from nucleus tractus solitarii, 795
Melanocyte-stimulating hormone
grooming behavior and, 833
nucleus tractus solitarii, 797
Membrane channels. *See* Ion channels
Membrane currents. *See also* Ion channels; *specific ion channels*
early concepts of membrane excitability, S49–S50
Hodgkin-Huxley revolution, S50–S51
time integral, S1–S2
Membrane pores, S6. *See also* Ion channels, voltage-gated
Molecular biology
voltage-dependent potassium channels, S69–S84. *See also* Potassium channels
voltage-gated sodium channels, S15–S41. *See also* Sodium channels
Mononuclear phagocytes, β-adrenergic receptors, 334
Monosynaptic reflex
afferent-motoneuron interface, 84–95
excitatory postsynaptic potential, 89–95. *See also* Postsynaptic potential
location of boutons on dendritic tree, 88–89
morphology of single-fiber connections, 85–89
number of synaptic boutons on motoneurons, 85–87
population of homonymous Ia synapses on motoneurons, 87–88
structure-function relationship, 71–95
afferent-motoneuron interface, 84–95
afferent system, 72–74. *See also* Afferent system
efferent system, 75–84. *See also* Motoneurons
Morphometric analysis, angiogenesis in skeletal and cardiac muscle, 371–372
Motoneurons, 75–84
axonal conduction velocity, axon diameter, and soma size, 77–78
dendritic morphology, 78–79
electrical models, 81–82
electrical properties, 81–84
motoneuron types, 83–84
soma vs. dendrite membranes, 82–83
excitability
cooperative factors and, 93
postsynaptic factors and, 92
presynaptic factors and, 92–93
Ia fiber interface with. *See* Monosynaptic reflex, afferent-motoneuron interface
morphology, 75–81
pool organization, 85
probablistic description, 80
size and structural complexity, 75–77
motor unit type and, 80
structure-related properties relevant for interpretation of electrophysiological results, 80–81
α- vs. γ-motoneurons, 79–80
Motor control, human. *See* Human motor control
Motor units
combination, responses of Golgi tendon organs, 639–640
single, activation of Golgi tendon organs, 636–639
Movement. *See also* Human motor control
cerebellar lesions and, 970–971. *See also* Cerebellum
visual guidance of, cerebellum in. *See* Cerebellum
Mucociliary clearance, β-adrenergic receptors in, 329–330
Mucosal immunity, 853–873
antigen delivery into organized mucosal lymphoid tissue, 857–861
follicle-associated epithelium, 857
M-cell apical membranes and antigen adherence, 857–860
M-cells as entry site for pathogenic microorganisms, 861
transcytosis of antigens by M-cells, 860–861
diffuse mucosal lymphoid tissue, 856–857
enterocyte role in antigen presentation, 857
intraepithelial lymphocytes, 856
lamina propria lymphocytes, 857
enhancement of, 872–873
immune responses in organized mucosal lymphoid tissue, 861–863
mucosal B-cell commitment to immunoglobulin A expression, 862–863
secretory immunoglobulin A in regulation of, 863
immunization strategies, 871–873
strategies to enhance mucosal immune response, 872–873
vaccine delivery to organized mucosal lymphoid tissue, 871–872
inert particulate carriers, 871–872
live vaccine vectors, 872
vaccine requirements, 871
lymphocyte migration and homing, 863–866
cell adhesion molecules in lymphocyte-high endothelial venule interactions, 864–866
distribution of homing specificities in mucosal tissue, 864
modulation of homing specificities, 866
mucosal effector molecule production and transepithelial transport, 866–868
immunoglobulin A antibodies, 867–868
secretory immunoglobulin A: mucosal effector antibody, 866–867
organization of mucosal lymphoid tissue, 854–857
diffuse, 856–857
organized, 855–856

organized mucosal lymphoid tissue, 855–856
antigen delivery into, 857–861
antigen-presenting cells, 856
immune responses in, 861–863
lymphoid cells, 855–856
vaccine delivery into, 871–872
secretory immunoglobulin A in, 866–867
experimental analysis of sIgA protection in vivo, 869–870
immune exclusion, 868–869
mechanisms of immune protection, 868–870
Mullerian-inhibiting substance, 740
Muscarinic receptors, in airways, 706–708
Myocardial infarction
angiogenesis in, 387–389
infarct size, fatty acid levels and, 919–920
Myocardial ischemia
cardiac triacylglycerol-fatty acid cycle in, 911
cardiac triacylglycerols in, 909–910
hydrolysis, 910–911
synthesis, 910
eicosanoid production in, 916–918
fatty acid metabolism, 906–918
accumulation of fatty acids and esters in, 907–908
decreased fatty acid oxidation, 907
eicosanoid production, 916–918
endogenous triacylglycerols, 909–911
origin of fatty acids in, 908
phospholipid metabolism, 911–916
platelet-activating factor, 918
lipoprotein lipase in, 911
lysophospholipids in, 922–923
phospholipid metabolism, 911–913
degradation, 911–912
consequences of, 916
mechanisms underlying, 913–914
impaired phospholipid formation, 915
subcellular loss of phospholipids, 912–913
platelet-activating factor in, 918
reperfusion in. *See* Heart, reperfused
Myoclonus, cerebellar lesion and, 1004

N

Natriuresis, immersion and
characterization of, 574–575
in cirrhosis, 598–603
in cirrhosis. *See* Liver disease, decompensated
decreased sodium reabsorption in
aldosterone suppression and, 576
altered transcapillary Starling forces and, 580
atrial natriuretic factors and, 577–578
dopamine and, 579
humoral inhibitor of sodium transport and, 580–581
kallikrein-kinin system and, 579–580
mechanisms of, 576–581
nephron sites of, 575–576
renal prostaglandin alterations and, 576–577
sympathetic nervous system activity and, 578–579
mechanisms of, 575–581, 576–581
in cirrhosis, 599–600
Natriuretic factors, stretch-induced release, 245–246
Neocortex, 5-hydroxytryptamine immunoreactive fibers in, 183
Neonate. *See* Infant; Perinatal period
Nephrotic syndrome, immersion studies, 603–605
Nerve, membrane currents. *See* Ion channels; Membrane currents
Nerve growth factor
gonadal, 754
regulation of sodium channel expression in neurons, S39
Nerve terminals, sodium channels in, S36–S37
Nervous system
airway control. *See* Airways, neural control
central
arterial blood pressure control, 235–236
Golgi tendon organ actions, 647–657
in human motor control, 34–38
serotonin system. *See* Brain serotonin system
taurine in, 105–106
grooming behavior, peripheral vs. central control, 832–833
sympathetic, natriuresis of immersion and, 578–579
Neuron network
dendritic neuron models. *See* Dendritic neuron models
vertebrate retina, 496–497
white-noise analysis, 501
Neurons
dendritic neuron models. *See* Dendritic neuron models
ionic channels, S160–S161
sodium channels in, S34–S37
regulation of expression, S38–S39
developmental regulation in brain and retina, S38–S39
nerve growth factor regulation, S39
tissue-specific gene expression, S39
Neurons, serotonergic. *See* Brain serotonin system
Neuropeptide(s). *See also* Neurotransmitters; *specific neuropeptides*
colocalization with medullary serotonergic neurons, 170–171
ovarian, 763–764
receptors, in airways, 709–711
serotonergic neuron growth and, 186
Neuropeptide Y
in airways, 710–711
nucleus tractus solitarii, 797
in cardiovascular regulation, 806–807
ovarian, 764
Neurophysiology, white-noise analysis, 491–504. *See also* White-noise analysis
Neurotensin, nucleus tractus solitarii, 798
in cardiovascular regulation, 808–809
Neurotoxins
molecular probes for sodium channel studies, S17–S19
α-scorpion toxin, sodium channel receptor site, S28
Neurotransmitters. *See also* Neuropeptides; *specific neurotransmitters*
adrenocorticotropic hormone-induced grooming and, 837–838
nucleus tractus solitarii, 796–798
in cardiovascular regulation, 799–813. *See also* Nucleus tractus solitarii
receptors, in airways, 705–713
release from airway nerves
control of. *See* Airways, neuromodulation
quantitation of neurotransmitter overflow, 700–701
serotonergic neuron growth and, 185–186
Neutrophils, β-adrenergic receptors, 333–334
Nicotinic acetylcholine-gated channels, S123–S132
acetylcholine binding sites, S129–S131
cloning, subunit sequences, and subunit similarity, S124–S127
pore lining, S131–S132
subunit composition and three-dimensional structure, S124
subunit structure, S127–S129
superfamily of channels, S123
Nicotinic receptors, in airways, 708
Nociception, brain serotonergic neuron activity and, 206

Nodes of Ranvier, sodium channels in, S35
Norepinephrine, nucleus tractus solitarii, in cardiovascular regulation, 799–800
Nuclear magnetic resonance, gramicidin channels, S119–S120
Nucleus raphe magnus, serotonergic neurons in, 170
Nucleus raphe obscurus, serotonergic neurons in, 169–170
Nucleus raphe pallidus, serotonergic neurons in, 170
Nucleus tractus solitarii
acetylcholine in, cardiovascular regulation and, 801–802
adrenocorticotropic hormone in, 797
amino acid neurotransmitters in, cardiovascular regulation and, 802–804
angiotensin II in, 798
cardiovascular regulation and, 807–808
atrial natriuretic peptide in, 798
cardiovascular regulation and, 808
bombesin in, 798
calcitonin gene-related peptide in, 798
cardiovascular regulation and, 808
calcitonin in, cardiovascular regulation and, 808
in cardiovascular regulation, 789–813
baroreceptor, 798
neuroanatomic aspects, 790–799
neurotransmitters/modulators in, 799–811. *See also specific neurotransmitters*
nucleus tractus solitarii as possible site of interaction of centrally acting antihypertensive drugs and endogenous opioid peptides, 811–812
cholecystokinin in, 798
corticotropin-releasing factor in, 796
dopamine in, cardiovascular regulation and, 800–801
dynorphins in, 797
β-endorphin in, 797
enkephalins in, 797
epinephrine in, cardiovascular regulation and, 800
functional topography, 798–799
baroreceptor, 798–799
gastric motility, 799
gustatory, 799
respiratory, 799
galanin in, 798
histamine in, cardiovascular regulation and, 801
α-melanocyte-stimulating hormone in, 797
γ-melanocyte-stimulating hormone in, 797
neuronal afferents to, 793–794
forebrain areas, 794
lower brain stem, 794
peripheral inputs, 793–794
spinal cord, 794
neuronal projections from, 794–796
ambiguus and dorsal vagal nuclei, 795
forebrain structures, 795–796
pontine structures, 795
spinal cord, 795
ventrolateral medulla, 795
neuropeptide Y in, 797
cardiovascular regulation and, 806–807
neurotensin in, 798
cardiovascular regulation and, 808–809
neurotransmitters in, 796–798
cardiovascular regulation and, 799–813. *See also specific neurotransmitters*
norepinephrine in, cardiovascular regulation and, 799–800
opioid peptides in, cardiovascular regulation and, 809–810
oxytocin in, 797
cardiovascular regulation and, 805
proopiomelanocortin-derived peptides in, cardiovascular regulation and, 811
serotonin in, cardiovascular regulation and, 801
somatostatin in, 796
cardiovascular regulation and, 809
substance P in, 797
cardiovascular regulation and, 804–805
tachykinins in, cardiovascular regulation and, 804–805
thyrotropin-releasing hormone in, 796
cardiovascular regulation and, 809
topography and cytoarchitecture, 790–793
vasoactive intestinal polypeptide and peptide histidine isoleucine in, 797
vasopressin in, 797
cardiovascular regulation and, 805–806
Nystagmus, cerebellar lesion and, 1003–1004

O

Oncogenes, c-*mos*, gonadal, 764–765
Ontogenesis
hemoglobin types and red blood cell populations in avian embryo, 942–943
ovary, 733
testis, 731
Oocyte meiosis inhibitor, 743–745
Opioid peptides
endogenous circulating, immersion and, 595
nucleus tractus solitarii, 797
in cardiovascular regulation, 809–810
interaction of centrally acting antihypertensive drugs with, 811–812
Opioids
in airways, 712
grooming behavior and
aberrant grooming, 836–837
peptide-induced excessive grooming, 836
Optokinetic reflex, cerebellum in, 993
Osmoregulation
extracellular, 237
taurine in, 108–113, 142–143
Ouabain theory, arterial pressure and blood volume changes, 266
Ovary
cell-cell interactions, 734–735
c-*mos* oncogene, 764–765
feedback of ovarian hormones on gonadotropin secretion, 734
follicles, 733
atresia, 734
gonadotropin-binding inhibitors, 763
gonadotropin surge-inhibiting factor, 762–763
luteinization inhibitor and stimulator, 762
neuropeptides, 763–764
nonsteroidal signals originating in. *See* Gonadal peptides
ontogenetic issues, 733
ovulation and corpus luteum formation, 734
plasminogen activator in, 747
role of gonadotropin and localization of luteinizing hormone and follicle-stimulating hormone receptors, 733–734
Ovulation, 734
Oxidants
respiratory β-adrenergic receptor function and, 348
serotonergic neuron growth and, 185
Oxygen
carrying capacity of blood, erythropoietin production and, 456–457
partial pressure

in embryonic blood (avian), 944–945
hypoxia and, 960
influence on timing of switch from embryonic to adult hemoglobin production, 961
in embryonic tissue (avian), 946–947
Oxygen free radicals. *See* Oxidants
Oxygen transport, in embryonic blood. *See* Blood oxygen transport, in early avian embryo
Oxytocin
gonadal, 758–759
nucleus tractus solitarii, 797
in cardiovascular regulation, 805

P

Paramyotonia congenita, genetic mutations in human sodium channel genes, S40
Pediatric population, maturation of locomotor pattern, 49–50
Peptide histidine isoleucine, nucleus tractus solitarii, 797
Peptides, taurine-containing, 142
Perception, Golgi tendon organ actions in, 656–657
Perinatal period, 507, 508
exogenous carbohydrate supply, 512–513
exogenous fatty acid supply, 517
gluconeogenesis
appearance of, 513–516
fatty acid oxidation in regulation of, 524–526
hormonal induction of cytosolic phosphoenolpyruvate carboxykinase, 514
increase in gluconeogenic enzyme activities, 513–514
liver oxygenation and, 514–515
maturation of mitochondrial oxidative capacity and, 515
pathway of gluconeogenesis, 513
short-term hormonal control of gluconeogenesis, 515–516
glucose and fatty acid metabolism during, 511–526
crucial role of fatty acid oxidation in regulation of gluconeogenesis, 524–526
exogenous carbohydrate supply, 512–513
exogenous fatty acid supply, 517
in human neonates, 541–543
initiation of gluconeogenesis, 513–516
intrahepatic regulation of fatty acid oxidation and ketogenesis, 518–524
liver glycogenolysis, 511–512
mobilization of triacylglycerol stores, 516–517
glucose metabolism, brown adipose tissue, 526
hormonal changes in, 509–510
intrahepatic regulation of fatty acid oxidation and ketogenesis, 518–524
carnitine availability and, 521
hormonal control of fatty acid oxidation and ketogenesis, 523–524
increase in activity of enzymes of fatty acid oxidation and ketogenesis, 520–521
malonyl-coenzyme A concentration and, 521–522
metabolic fate of mitochondrial acetyl-coenzyme A, 522–523
partition of long-chain fatty acyl-CoA between triacylglycerol and acylcarnitine formation, 520
pathways for fatty acid oxidation and ketogenesis, 518–520
regulation of carnitine palmitoyltransferase activity by substrates and effectors, 521–522
regulation of fatty acid uptake and acyl-coenzyme A formation, 520
sensitivity of carnitine palmitoyltransferase I to malonyl-coenzyme A inhibition, 521–522
lipid metabolism, brown adipose tissue, 526–528
mobilization of triacylglycerol stores
in liver, 517
in white adipose tissue, 516–517
nutritional changes: diet composition and feeding behavior, 508
thermogenesis and brown adipose tissue metabolism, 526–528
fatty acid oxidation and expression of uncoupling protein, 526
glucose metabolism, 526
lipid metabolism, 526–528
hormonal control, 527–528
uptake of circulating triacylglycerols, 526
Periodic paralysis, molecular mechanisms, S40–S41
pH
blood, in avian embryo, 945–946
blood carbon dioxide partial pressure and, 946
erythrocyte
in avian embryo, extracellular pH and, 948–949
membrane ion transport and, 302–310
intracellular
distal nephron potassium channels and, 17
potassium conductance in Henle's loop and, 10–11
proximal renal tubular potassium channels and, 4
tissue, in avian embryo, 947–948
Pheochromocytoma, immersion studies in, 611
Phosphagens, 136–138
Phosphatases, in cell volume regulation, 1043–1044
Phosphate
erythrocyte content
in avian embryo, 954–955
hypoxia and, 961
effect on hemoglobin-oxygen affinity, 302
ion pumping and, 302
influence on aggregation of embryonic hemoglobin P and hemoglobin D (avian), 955–956
Phosphoenolpyruvate carboxykinase, cytosolic, hormonal induction of, in perinatal period, 514
Phospholipids
cardiac, 897–900
ischemia and reperfusion and, 911–916
taurine interactions, 119–123
Physical fitness, renal and hormonal responses to immersion and, 568
Physical training
angiogenesis in cardiac muscle and, 379–380
angiogenesis in skeletal muscle and, 380–381
Pituitary, potassium channels in, S83
Plants, taurine in, 104–105
Plasma
arginine vasopressin level, immersion and, 584–585
atrial natriuretic factor, immersion and, 591–592
Plasma osmolality, arginine vasopressin suppression during immersion and, 588
Plasminogen activator, gonadal, 746–748
ovarian, 747
testicular, 747–748
Platelet-activating factor
cardiac production and function, 906
ischemia and reperfusion and, 918
respiratory β-adrenergic receptor function and, 347
Platelet-derived growth factor, gonadal, 754
P-Mod-S, testicular, 761
Pointing
cerebellar lesion and, 1005
cerebellum in, 1000–1003
Pontine structures
neuronal projections from nucleus tractus solitarii, 795
in visual guidance of movement. *See* Cerebellum, visual guidance of movement

visual responses in pons, 977–978
Postsynaptic potential, excitatory (EPSP), 89–95
analysis of quantal events, 90–92
cooperative factors that influence motoneuron excitability, 93–94
postsynaptic factors that can determine motoneuron excitability, 92
presynaptic factors that can determine motoneuron excitability, 92–93
single-fiber, 89
unit, 90
Postural reflexes
cerebellar lesion and, 1004
in geriatric population, 50
gravity and, 42–43
Posture
human. *See also* Human motor control
adjustments during voluntary arm and leg movements, 35–36
adjustments to perturbations, 36
vestibular system in, 44–46
visual system in, 46–47
visual destabilization of, 47
Potassium, secretion, distal nephron potassium channels and, 19
Potassium channels. *See also* Ion channels, voltage-gated
in airway neuromodulation, 717
cloning and characterization of potassium channel superfamily, S70–S77
novel properties of vertebrate A-type channels, S77
potassium channel gene family in *Drosophila*, S74–S75
potassium channel gene family in vertebrates, S75–S77
Shaker channel gating, S72–S74
Shaker channel inactivation, S70–S72
Shaker channel selectivity, S74
Shaker potassium channels, S70
conductance, measures of, S6
in distal nephron, 15–19
cell membrane potential and, 16
cell volume and, 17
hormones and mediators and, 17–18
hydrogen ion secretion and, 19
intracellular adenosine triphosphate and, 17
intracellular calcium and, 17
intracellular pH and, 17
intracellular potassium and sodium concentrations and, 16–17
potassium secretion and, 19
regulation of, 16–19
sodium reabsorption and, 18–19
future directions, S62
gating, S51–S56
anomalous kinetic observations, S52
bursts of openings, S54–S55
dilemmas in channel gating, S52–S53
Hodgkin-Huxley model, S51–S52
how the gate is opened, S56–S57
identical and independent subunit hypothesis, S55–S56
single Hodgkin-Huxley potassium channels, S53
structures underlying, S56
gating factors, S7
genes, human, S84
in Henle's loop, 9–13
cell membrane potential and, 10
cell volume and, 11–12
divalent ion transport and, 13
hormones and mediators and, 12
intracellular adenosine triphosphate and, 11
intracellular calcium and, 11
intracellular magnesium and, 11
intracellular pH and, 10–11
intracellular sodium and potassium concentrations and, 10
potassium transport and, 13
sodium chloride transport regulation and, 12–13
molecular biology, S69–S84
cloning and characterization of potassium channel superfamily, S70–S77
human potassium channel genes, S84
identified native voltage-dependent potassium channels, S82–S84
pharmacology of cloned channels, S77–S81
structural model of potassium channel, S81–S82
native voltage-dependent potassium channels, S82–S84
in heart, S83–S84
in lymphocytes, S83
in pituitary, S83
Shaker potassium channels, S82–S83
permeation, S58–S62
are sodium and potassium channels physically distinct, S58–S59
can more than one type of ion occupy the channel at the same time, S60–S61
conductance and permeation, S59
does more than one potassium ion occupy the channel at any one time, S60
how to model, S61–S62
independence principle, S59
selectivity for potassium ions, S61
pharmacology of cloned channels, S77–S81
charybdotoxin, S79–S80
dendrotoxin, S80–S81
tetraethylammonium, S78–S79
in proximal renal tubule, 3–8
cell membrane potential and, 3–4
intracellular calcium and, 4–5
intracellular pH and, 4
intracellular potassium and sodium concentrations and, 4
in renal epithelial transport regulation, 1–20. *See also* Renal epithelial transport
selectivity for potassium ions, S61
sigmoid opening, exponential closing, S8–S9
structural model, S81–S82
structure and function
how the gate is actually opened, S56–S57
structures underlying channel gating, S56
tetrameric structure of channel and n^4 kinetics, S57–S58
voltage-gated. *See also* Potassium channels
Hodgkin-Huxley paradigm, S49–S62
molecular biology, S69–S84
voltage sensitivity, S8
Pregnancy, relaxin in, 741, 742–743
Pressure natriuresis-diuresis
angiotensin and, 253
arachidonate metabolites and, 253–255
atrial natriuretic factor and, 255–256
current hypothesis, 251–253
endothelin and, 256
extracellular volume and, 247–249
glomerular filtration and, 249
in long-term arterial pressure regulation, 256–261
body fluid volume and renal arterial pressure servo-control studies, 260–261
effects of sodium-retaining hormones on long-term level of arterial pressure (chronic renal function curves), 259–260
inability of other systems to sustain pressure control, 258
reduced renal excretory function and hypertension, 258–259
renal cross-transplantation studies, 259

neural, endocrine, paracrine, and autocrine influences, 253–256
proposed mechanisms, 249–253
renal kallikrein-kinin system in, 255
tubular reabsorption and, 249–251
vasopressin and, 256
Prism adaptation, short-term, cerebellum in, 999–1000
Prodynorphin, gonadal, 757
Proenkephalin, gonadal, 757
Proopiomelanocortin peptides
gonadal, 756–757
nucleus tractus solitarii, in cardiovascular regulation, 811
Proprioceptive reflex systems
in human motor control, 38–44. *See also* Human motor control
in rigidity, 56–57
in spastic paresis, 54–55
Prostaglandins. *See also* Arachidonate metabolites
in airways, 714–715
PGF
relationship to renin-aldosterone system, 589–590
urinary excretion
immersion and, 588–589
urine flow rate and, 590
renal
immersion and, 588–590. *See also* Water immersion, renal effects in humans
in cirrhosis, 600–601
natriuresis of immersion and, 576–577
Prostanoids. *See also* Arachidonate metabolites
erythropoiesis and, 461
Protein(s)
dietary, glycogen repletion and, 1029–1030
extracellular matrix. *See* Extracellular matrix proteins
folding and assembly, heat shock proteins in, 1071–1073
heat shock. *See specific heat shock proteins*; Stress response
regulatory, in airway neuromodulation, 718
serotonergic neuron growth and, 1878
stress. *See* Stress response
taurine interactions, 123–129
Protein kinase, in cell volume regulation, 1043–1044
Protein kinase C
modulation of brain sodium channels, S31–S32
modulation of other sodium channels, S32
Proteoglycans. *See* Extracellular matrix proteins
Protons, hemoglobin-oxygen affinity and, 303
Purinoceptors, in airways, 711–712

R

Radioprotection, cysteamine and, 133–134
Rarefaction, vascular, blood volume changes and, 276–278
Reaching movement, cerebellum in, 1000–1003
Reaction time
cerebellar lesion and, 1004–1005
cerebellum in, 998–999
Reactive oxygen species. *See* Oxidants
Recombinant human erythropoietin. *See* Erythropoietin, clinical applications
Red blood cells. *See* Erythrocyte
Reflexes, cerebellar control, 991–995
Relaxin, 741–743
in estrous cycle, 741–742, 743
functions in females, 742–743
functions in males, 743
localization, 741–742
in pregnancy, 741, 742–743
regulation, 742
structure, 741
Renal epithelial transport
distal convoluted tubule and collecting duct, 13–19
hydrogen ion secretion, potassium channels in, 19
integrated transport functions, potassium channels in, 18–19
potassium channels and potassium conductance in, 15–16
cell membrane potential and, 16
cell volume and, 17
hormones and mediators and, 17–18
intracellular adenosine triphosphate and, 17
intracellular calcium and, 17
intracellular pH and, 17
intracellular potassium and sodium concentrations and, 16–17
regulation of, 16–18
potassium secretion, potassium channels in, 19
sodium reabsorption, potassium channels in, 18–19
transport systems, 13–14
loop of Henle, 8–13
integrated transport function, role of potassium channels in, 12–13
potassium channel regulation and sodium chloride transport regulation in thick ascending limbs, 12–13
potassium channels and potassium conductance in, 9–10
cell membrane potential and, 10
cell volume and, 11–12
hormones and mediators and, 12
intracellular adenosine triphosphate and, 11
intracellular calcium and, 11
intracellular magnesium and, 11
intracellular pH and, 10–11
intracellular sodium and potassium concentrations and, 10
regulation of, 10–12
potassium channels in regulation of thick ascending limb and dilating segment potassium transport, 13
potassium channels in regulation of thick ascending limb transport of divalent ions, 13
transport systems, 8–9
potassium channels in, 1–20
proximal renal tubule, 2–8
homeostatic role of potassium channels during inhibition of sodium-potassium-adenosinetriphosphatase, 8
homeostatic role of potassium channels during stimulated sodium-coupled transport, 7–8
integrated transport function, role of potassium channels in, 7–8
potassium channels and potassium conductance in, 3
cell membrane potential and, 3–4
cell volume and, 5–6
hormones and mediators and, 6
intracellular calcium and, 4–5
intracellular pH and, 4
intracellular potassium and sodium concentrations and, 4
regulation of, 3–7
transport systems, 2–3
transport systems sensitive to potassium channel activity, 7
Renin
arterial blood pressure control and, 235
erythropoiesis and, 461
gonadal, 760
vascular wall, 270
Renin-angiotensin-aldosterone system
atrial stretch receptors and, 242–243
immersion and, 581–583
renal prostaglandin E and, 589–590
Renin-angiotensin system, arginine vasopressin suppression during immersion and, 587–588

Respiration, nucleus tractus solitarii in, 799
Respiratory physiology, blood oxygen transport in early avian embryo. *See* Blood oxygen transport, in early avian embryo
Respiratory tract, β-adrenergic receptor localization and function
airway epithelium, 329, 330–331
airway smooth muscle, 328–329
cholinergic transmission, 328
ciliated cells and mucociliary clearance, 329–330
sympathetic innervation and regulation of airway tone, 328
Retina
sodium channels, developmental regulation of expression, S38–S39
taurine in, 106
vertebrate
amacrine cells, 498–499
neuron network, 496–497
white-noise analysis, 496–500
Rigidity, 55–57
central mechanisms in, 56
proprioceptive reflexes and muscle tone in, 56–57

S

Saccades. *See* Eye movements
Saxitoxin, voltage-dependent channel blockade, S135–S136
α-Scorpion toxin, sodium channel receptor site, S28
Seminal plasma inhibins, 739–740
Sensory stimulation, brain serotonergic neuron activity and, 202–203
Serotonin. *See also* 5-Hydroxytryptamine
in airways, 714
central nervous system. *See* Brain serotonin system
nucleus tractus solitarii, in cardiovascular regulation, 801
Sex steroids, erythropoiesis and, 462
Signal transduction, erythropoietin, 466–467
Skeletal muscle
afferent-motoneuron interface, 84–95
afferent system, 72–74
amino acid oxidation, 423–427
acid-base and energy balances, 427
atrophy, angiogenesis and, 385–386
capillary growth in. *See* Angiogenesis
capillary supply during phylogeny, 373–376
collateral circulation, development of, 392–393
efferent system, 75–84. *See also* Motoneurons
glucose and fatty acid metabolism, in suckling-weaning transition, 535–537
Golgi tendon organs, 623–658. *See also* Golgi tendon organs
grafts, angiogenesis in, 386–387
in human posture and locomotion. *See* Human motor control
hyperkalemic periodic paralysis, genetic mutations in human sodium channel genes, S40
hypertrophy, angiogenesis and, 385–386
monosynaptic reflex. *See* Monosynaptic reflex
paramyotonia congenita, genetic mutations in human sodium channel genes, S40
regeneration, angiogenesis in, 386
sodium channels in, S36
genetic mutations in human sodium channel genes, S40–S41
regulation of expression, S37–S38
developmental, S37–S38
effects of innervation/denervation, S38
electrical activity and, S38
vascular growth during development, 377
Sleep-wake-arousal cycle, brain serotonergic neuron activity in, 199–202
Sodium
intracellular
distal nephron potassium channels and, 16–17
potassium conductance in Henle's loop and, 10
proximal renal tubular potassium channels and, 4
reabsorption
decreased, in immersion. *See* Natriuresis, immersion and
distal nephron potassium channels and, 18–19
renal handling, immersion and, 574–581. *See also* Water immersion, renal effects in humans
transport, humoral inhibitor of, natriuresis of immersion and, 580–581
Sodium channel blockers, sodium channel receptor site, S28–S29
Sodium channels. *See also* Ion channels, voltage-gated
activation, voltage-dependent conformational change associated with, S17
assembly, role of β1- and β2-subunits in, S34
biosynthesis, S33–S34
function, physiological modulation, S30–S32
gating factors, S7
genetic mutations in human sodium channel genes, S40–S41
hyperkalemic periodic paralysis, S40
molecular mechanisms of periodic paralyses, S40–S41
paramyotonia congenita, S40
glycosylation of subunits, S32
inactivation, intracellular components involved in, S17
interaction with glia, S37
ion conductance and ion selectivity filter, S16–S17
isolation of, S19–S21
localization in excitable cells, S34–S37
determinants of localization, S36–S37
differential distribution of sodium channel subtypes, S36
glycosylation in, S36
immobilization of sodium channels, S36–S37
interaction with glia, S37
neurons, S34–S36
skeletal muscle, S36
molecular properties inferred from functional studies, S16–S17
intracellular components involved in inactivation, S17
ion conductance and ion selectivity filter, S16–S17
voltage-dependent conformational change associated with activation, S17
in neurons, S34–S36
axon initial segments, S34–S35
nerve terminals, S35–S36
nodes of Ranvier, S35
regulation of expression, S38–S39
neurotoxins as molecular probes for, S17–S19
physiological modulation of function, S30–S32
cAMP-dependent protein phosphorylation modulation of brain sodium channels, S30–S31
cAMP-dependent protein phosphorylation modulation of other sodium channels, S31
G proteins in modulation, S32
protein kinase C modulation of brain sodium channels, S31–S32
protein kinase C modulation of other sodium channels, S32
posttranslational modifications, S32–S33
purification and reconstitution of function, S19–S23
covalent labeling of polypeptide components, S19
isolation of sodium channels, S19–S21
molecular mass of solubilized sodium channel, S20
radiation inactivation, S19
reconstitution of function from purified components, S21–S23
sodium channel subunits in membrane, S19
solubilization and purification, S19–S20

subunit composition of purified sodium channel, S20–S21
reconstitution of function from purified components, S21–S23
ion flux, S21
single-channel recording, S22–S23
voltage-dependent neurotoxin binding, S21–S22
regulation of expression, S37–S39
neurons, S38–S39
skeletal muscle, S37–S38
sigmoid opening, exponential closing, S8–S9
in skeletal muscle, S37
genetic mutations in human sodium channel genes, S40–S41
regulation of expression, S37–S38
structure and function, S23–S30
functional expression of subunits, S24–S25
functional map of α-subunits, S25–S30
primary structures of α-subunits, S23–S24
primary structures of β-subunits, S24
α-subunits
functional expression, S24–S25
functional map of, S25–S30
inactivation, S27–S28
primary structures, S23–S24
receptor site for blockers of sodium channels, S28–S29
receptor site for α-scorpion toxins, S28
transmembrane pore, S29–S30
voltage-dependent activation, S25–S27
β-subunits
functional expression, S24–S25
primary structures, S24
role in posttranslational assembly, S34
voltage-gated
biosynthesis, posttranslational processing, and assembly of, S32–S34
cellular and molecular biology, S15–S41
localization in excitable cells, S34–S37
molecular properties inferred from functional studies, S16–S17
naturally occurring mutations in human sodium channel genes, S40–S41
neurotoxins as molecular probes for, S17–S19
physiological modulation of function, S30–S32
purification and reconstitution of sodium channel function, S19–S23
regulation of expression, S37–S39
structure and function, S23–S30
voltage sensitivity, S8

Sodium chloride, transport in Henle's loops, potassium channels and, 12

Somatostatin
nucleus tractus solitarii, 796
in cardiovascular regulation, 809
ovarian, 764

Spaceflight, manned, immersion studies as experimental analogue of, 611–612

Spastic paresis, 53–55
central mechanisms in, 54
proprioceptive reflexes in, 54–55
reflex effects and muscle tone in, 55

Spinal cord
Golgi tendon organ actions, 656–657. *See also* Golgi tendon organs
Ib afferent fiber trajectories, 627
monosynaptic reflex. *See* Monosynaptic reflex
muscle spindle Ia fibers, 72–73
muscle spindle II fibers, 73
neuronal projections from nucleus tractus solitarii, 795
nucleus tractus solitarii afferents in, 794

Starling forces, transcapillary, natriuresis of immersion and, 580

Stereological analysis, angiogenesis in skeletal and cardiac muscle, 370–371

Stress, brain serotonergic neuron activity and, 205–206

Stress response, 1063–1077
changes in cell physiology, 1064–1065
in disease and medicine, 1074–1077
heat shock proteins in cells experiencing stress and their possible mode of regulation, 1073–1074
heat shock proteins in protein folding and assembly, 1071–1073
immunology and, 1076–1077
induction of response, 1063–1064
as marker for cell injury, 1074, 1076
structure and function of stress proteins, 1065–1071
glucose-regulated protein 24, 1070
heat shock protein 28, 1067–1068
heat shock protein 60 (groEL) family, 1068–1069
heat shock protein 70 family, 1070–1071
heat shock protein 90 family, 1069–1070
heat shock protein 110, 1070
ubiquitin, 1066–1067
toxicology and, 1077

Stretch reflexes, in human posture and locomotion, 38–40

Substance P
nucleus tractus solitarii, 797
in cardiovascular regulation, 804–805
ovarian, 764

Suckling-weaning transition, 507
development of overt obesity at weaning in model of genetic obesity: Zucker (*fa/fa*) rats, 541
glucose and fatty acid metabolism during, 528–541
brain metabolism, 534–535
development of overt obesity at weaning in Zucker (*fa/fa*) rat, 540–541
integrated aspects of energy metabolism during suckling, 540–541
intestinal metabolism, 539–540
kidney metabolism, 533–534
liver metabolism, 528–533
muscle metabolism, 535–537
white adipose tissue metabolism, 537–539
hormonal changes in, 510–511
nutritional changes: diet composition and feeding behavior, 508–509

Surfactant, taurine as, 139–141

T

Tachykinins
in airways, 709–710
nucleus tractus solitarii, in cardiovascular regulation, 804–805

Taste perception, nucleus tractus solitarii in, 799

Taurine
antioxidant effect, 135–136
biochemical considerations, 104
distribution, 104–107
metabolism, 107–108
biological actions, 102
calcium modulation, 114–119
calcium binding and transport, 115
calcium detectors, 119
calcium movements, 115–119
as energy source, 138–139
energy storage by, 136–138
metabolic actions: taurine as precursor
antioxidation, 135–136
energy storage, 136–138

isethionic acid and anion balance, 141–142
metabolism and energy production, 138–139
radioprotection, 136
surfactant and detergent action, 139–141
taurine-containing peptides, 142
taurine metabolites, 142
xenobiotic conjugation, 141
metabolic actions: taurine as product
antioxidation, 130–133
cysteine detoxification, 134–135
radioprotection, 133–134
metabolism, 107–108
nonmetabolic actions, 108–130
in osmoregulation, 108–113, 142–143
phospholipid interactions, 119–123
physicochemical considerations, 102–104
physiological actions, 101–144
protein interactions, 123–129
radioprotection by, 136
release, 112–113
surfactant and detergent actions, 139–141
uptake, 112
xenobiotic conjugation, 141
zinc interactions, 129–130
Teleosts
adrenergic control of hemoglobin-oxygen affinity in, 311–314
erythrocyte pH, effects of secondarily active ion transport mechanisms, 308–310
Temperature, environmental, angiogenesis in skeletal muscle and, 379
Tendon organs. *See* Golgi tendon organs
Testis
cell-cell interactions, 733
clusterin, 761–762
c-*mos* oncogene, 764–765
gonadotropin effects, 732
morphological characteristics in adult, 731–732
nonsteroidal signals originating in. *See* Gonadal peptides
ontogenetic issues, 731
plasminogen activator in, 747–748
P-Mod-S, 761
remodeling of tissue, 732
stages of gametogenesis, 732
Tetraethylammonium, binding by cloned potassium channels, S78–S79
Tetrodotoxin, voltage-dependent channel blockade, S135–S136
Thermogenesis, in neonate, 526
Thermoregulation, brain serotonergic neuron activity in, 203–204
Thyroid cell proliferation
adenosine 3′,5′-cyclic monophosphate, phosphatidylinositol bisphosphate, and tyrosine protein kinase cascades in, 678–679
apparently opposite programs: proliferation and differentiation expression induced by thyrotropin and adenosine 3′,5′-cyclic monophosphate cascade, 681–682
extracellular signals involved in control of, 673–675
iodine, 674
local signals, 674–675
other hormones, 674
pathological signals, 674
thyrotropin, 673–674
growth control and goitrogenesis, 682–686. *See also* Goitrogenesis
growth control ratio, 671
indexes of, 670–671
in normal thyroid tissue in vivo, 667–669
coordination between various thyroid cell types, 668–669
growth under stimulatory conditions, 668
physiological situation, 667–668
stem cells, 669
pathways regulating, 675–681
adenosine 3′,5′-cyclic monophosphate, phosphatidylinositol bisphosphate, and tyrosine protein kinase cascades in, 678–679
autocrine loop in, 681
effect of factors other than thyrotropin, 677–678
general considerations, 675–676
kinetics of biochemical events in various thyroid mitogenic pathways, 679–681
mitogenic and differentiating action of thyrotropin, 676–677
physiological and pathological regulation, 667–687
thyroid adenoma, 684–685
Thyroid growth. *See also* Thyroid cell proliferation
apparently opposite programs: proliferation and differentiation expression induced by thyrotropin and adenosine 3′,5′-cyclic monophosphate cascade, 681–682
cell proliferation in normal thyroid tissue in vivo, 667–669
coordination between various thyroid cell types, 668–669
growth under stimulatory conditions, 668
physiological situation, 667–668
stem cells, 668–669
differentiation, determination, differentiation expression, 671–673
model for thyroid, 672–673
thyroid system, 671–672
growth control and goitrogenesis, 682–686. *See also* Goitrogenesis
hormones and, 674
iodine and, 674
methodology for study of, cell proliferation indexes, 670–671
model systems for study of, 669–670
thyrotropin in, 673–674
working definition: growth control ratio, 671
Thyroid hormones
β-adrenergic receptor regulation and, 338
angiogenesis and, 397
erythropoiesis and, 462
Thyrotropin
mitogenic and differentiating action of, 676–677
thyroid cell proliferation and differentiation induced by, 681–682
thyroid growth and, 673–674
Thyrotropin-releasing hormone, nucleus tractus solitarii, 796
in cardiovascular regulation, 809
Thyroxine, angiogenesis and, 397
Tissue culture, fetal serotonergic neurons, 183–185
accelerated maturation, 184
target cell interaction, 184–185
Tissue hypoxia, erythropoietin production and, 456–461
cell cultures, 459–461
isolated perfused kidneys and livers, 458–459
overproduction, 467
whole organism, 456–458
increased blood oxygen affinity, 457–458
lowered arterial oxygen tension, 457
lowered blood oxygen capacity, 456–457
lowered renal blood flow, 458
T lymphocytes
β-adrenergic receptors, 334
in organized mucosal lymphoid tissue, 855
α-heavy chain isotype switch and, 862
Toxicology, stress response and, 1076–1077
Tracking
cerebellar lesion and, 1005
cerebellum in, 1000–1003
Training, human motor performance and, 51–52

Transduction, Golgi tendon organs, 629–633
Transforming growth factor-α, gonadal, 752
Transforming growth factor-β, gonadal, 753–754
Transplantation
cardiac, immersion studies in recipients, 609–610
renal, hypertension and, 259
serotonergic neurons, 190–194
descriptive studies and hyperinnervation, 191–192
electrophysiological maturation, 193
functional recovery, 193–194
host trophic factor, 192–193
role of target sites, 192
Tremor, cerebellar lesion and, 1005
Triacylglycerol
cardiac, 894–897
ischemia and, 909–911
mobilization in perinatal period, 516–517
liver stores, 517
white adipose tissue stores, 516–517
Tumors, erythropoietin overproduction and, 468

U

Ubiquitin, 1066–1067
Urea, erythrocyte, hemoglobin-oxygen affinity and, 310
Urine
arginine vasopressin secretion, immersion and, 583–584
cyclic nucleotide excretion, relationship to atrial natriuretic factor during immersion, 593
prostaglandin E excretion
immersion and, 588–589
urine flow rate and, 590

V

Vaccine. *See* Immunization
Vascular endothelium
electrical coupling, 270
endothelial contracting factor, 270
endothelin, 270–271
endothelium-derived relaxing factor, 270
in myogenic response, 269–271
vascular wall renin, 270
Vasoactive intestinal peptide
in airways, 709
nucleus tractus solitarii, 797
ovarian, 763–764
Vasodilatation, long-term, angiogenesis in skeletal and cardiac muscle and, 383–384
Vasopressin. *See* Arginine vasopressin
Vertebrates
A-type potassium channels in, S77
potassium channel gene family in, S75–S77
Vertigo, "height," 47
Vestibular system, in human motor control, 44–46
Vestibuloocular reflex
cerebellar lesion and, 1003
cerebellum in, 991–993
Vibrational spectroscopy, gramicidin channels, S119
Visual placing reflex, cerebellum in, 995
Visual system
cerebellum in visual guidance of movement, 967–1007. *See also* Cerebellum
compensation for defective afferent input, 46–47
destabilization of posture, 47
in human motor control, 46–47
visual cortex, localization of, 971–973
white-noise analysis, 496–500
generation of nonlinearities in amacrine cells, 498–499
linear modulation response, 497–498
neuron network of vertebrate retina, 496–497
signals encoded into spike trains, 499–500
spatiotemporal receptive fields, 500
Visuomotor psychophysics, 984–988
control strategies, 985
intermittent control, 985
motor memory, internal models, 986–987
theories of cerebellar function, 987–988
comparison, 987
motor learning, 987–988
parameter adjustment, 987
prediction, 987
timing, 987
visual signals, 985–986
Vitelline microcirculation, oxygenation in, 951–952

W

Water immersion
blood pressure and, in humans, 569
cardiac output and, in humans, 568–569
central blood volume response in humans, 568–569
mechanisms of increases, 570–572
redistribution of body fluid compartments and, 570–572
redistribution of regional blood flow and, 572
role of hydrostatic pressure gradient in, 570
comparison of central hemodynamic changes induced by immersion and saline administration, in humans, 569–570
differences between water immersion and saline-induced volume expansion, 572–573
as experimental analogue of manned spaceflight, 611–612
hemodynamic responses in humans, 568–572
blood pressure changes, 569
central blood volume and cardiac output changes, 568–569
circulating endogenous opioid peptides and, 595
in decompensated liver disease, 596–597
mechanism(s) of increases in central blood volume, 570–572
redistribution of regional blood flow, 572
hormonal responses in humans, physiological determinants, 595–596
natriuresis and. *See* Natriuresis, immersion and
renal effects in humans, 564–612
age and, 596
arginine vasopressin alterations, 583–588
atrial natriuretic factors increase and, 588
baroreceptors and, 586–587
influence of arginine vasopressin suppression on immersion-induced diuresis, 586
metabolic clearance of arginine vasopressin and, 587
plasma levels, 584–585
plasma osmolality and, 588
possible mechanisms of arginine vasopressin suppression, 586–588
renin-angiotensin system in, 587–588
urinary excretion of, 583–584
atrial natriuretic factor, 590–594
amino-terminal and carboxy-terminal portions of atrial natriuretic factor prohormone, 593
atrial natriuretic factor infusion vs. immersion-induced augmentation of atrial natriuretic factor, 592–593

plasma levels, 591–592
urinary cyclic nucleotide excretion and, 593
bath temperature, 567–568
catecholamines, 594–595
diurnal variation, 595–596
elucidation of afferent limb of immersion model, 568–572
historical background, 565–566
immersion facility, 566–567
immersion media, 567
intrarenal determinants of glomerular filtration rate, 574
inulin and *p*-aminohippurate clearances, 573
methodological considerations, 566–568
physiological determinants, 595–596
renal hemodynamic changes, 573–574
renal prostaglandins, 588–590
relationship of renal prostaglandin E and renin-aldosterone system, 589–590
urinary prostaglandin E, 588–589
urine flow rate and prostaglandin E excretion, 590
renal vasomotor response, 573
renin-angiotensin-aldosterone axis, 581–583
scope of review, 565
sodium handling, 574–581. *See also* Natriuresis, immersion and
characterization of natriuresis, 574–575
in cirrhosis, 598–603
mechanisms of natriuresis, 575–581
state of physical fitness, 568
studies in decompensated liver disease, 596–603
water handling in decompensated cirrhosis, 597–598
studies in cardiac transplant recipients, 609–610
studies in decompensated liver disease, 596–603
changes in central hemodynamics, 596–597
renal sodium handling, 598–603
renal water handling, 597
studies in diabetic patients, 610–611
studies in essential hypertension, 605–608
effects of antihypertensive agents on renal function, 608–609
studies in nephrotic syndrome, 603–605
studies in pheochromocytoma, 611
studies in primary aldosteronism, 611
therapeutic applications, potential, in decompensated liver disease, 602–603
Water transport, airway epithelium, β-adrenergic receptors in, 330–331
White adipose tissue
glucose and fatty acid metabolism, in suckling-weaning transition, 537–539
triacylglycerol stores, mobilization in perinatal period, 516–517
White-noise analysis, 491–504
advantages, 503–504
auditory system, 500
cascade structures, 501–503
computation of kernels, 493
procedures for application to neurophysiology, 493–496
spike trains, 496
theory, 491–493
visual system, 496–500
generation of nonlinearities in amacrine cells, 498–499
linear modulation response, 497–498
neuron network of vertebrate retina, 496–497
signals encoded into spike trains, 499–500
spatiotemporal receptive field, 500
Wiener kernels. *See* White-noise analysis

X

Xenobiotics, taurine conjugation, 141

Z

Zinc, taurine interactions, 129–130